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This project established the design and development of multifunctional PEO surface-
decorated silica nanocapsules (PEOSNs), whereby the capabilities of bioimaging, 
stimuli-responsiveness and specific targeting are effectively combined into a single 
nanocapsule. First, to develop a class of robust and colloidally stable silica 
nanocapsules, we have investigated the interfacial hydrolysis and condensation of 
silicon alkoxides that is confined between the PPO core and PEO corona of F127 
polymeric micelles. To demonstrate the silica nanocapsules as effective nanocarriers 
for bioimaging as well as their biocompatibility, in vivo studies with zebrafish as the 
vertebrate model were performed. Cellular internalization of these silica nanocapsules 
did not interfere with larval development nor affect vessel growth. Their biostability 
was also verified by the continued presence of fluorescent-labelled cells in the 
zebrafish larvae over a prolonged period. 
 
Next, we had studied the encapsulation of manganese oxide nanoparticles (MONs) for 
magnetic resonance imaging (MRI) in the detection of cancer cells. Herein, the hybrid 
silica nanocapsules were shown to be highly permeable and hydrophilic for optimal 
access of water molecules to encapsulated manganese oxide in the core. The nano-
encapsulation also conferred high colloidal stability to MONs by the surface 
decoration of PEO chains and a small overall diameter (<100 nm). Besides, the MONs 
thus encapsulated were not susceptible to Mn-ion leaching, and their biocompatibility 




To properly engineer MONs of high r1 relaxivity, the hybrid silica nanocapsules were 
also employed as a nanoreactor to ensure that acidic etching of MONs by an acetate 
buffer solution is highly controlled. As such, hollow MONs of high distinctness and 
homogeneity were successfully formed and they demonstrated superior r1 relativity of 
up to 2.58 mM-1s-1. By modifying the nanoreactor architecture, the efficacy of MONs 
as T1 MRI contrast agents were significantly improved if an optimal cluster of hollow 
MONs was encapsulated into the silica framework. By studying the evolution of core 
morphology with time, it was revealed that the hollow formation arose due to the 
surface stabilization of MONs by acetate ions and the subsequent acidic etching of the 
interior core in a sporadic manner. 
 
Finally, we have successfully developed a class of pH-activatable fluorescence/MR 
dual imaging nanoprobes based on the co-encapsulation of MONs and coumarin-545T 
(C545T) inside the hybrid silica nanoshell. In order to promote cancer cell targeting 
with high-specificity, the nanoprobes were also conjugated with folic acid (FA) to 
establish a greater affinity for cancer cells that over-express folate receptors (FR) on 
their cell membrane. In the new nanosystem, the MONs were shown to function as an 
efficient fluorescence quencher of C545T prior to cellular uptake. However, 
fluorescence recovery was achieved upon acidic dissolution of the MONs following 
receptor-mediated endocytosis into the low pH compartments of the cancer cells. 
Meanwhile, the Mn2+ ions thus released were also shown to exert a strong T1 contrast 
enhancement in the cancer cells. Therefore, by demonstrating the dual-activatable 
magnetic resonance (MR) and fluorescence imaging in response to the low pH 
conditions, it is envisioned that these nanoprobes would have tremendous potential for 
emerging cancer-imaging modalities, such as image-guided cancer therapy. 
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Chapter 1: Introduction 
 1 





Affecting millions of people of all ages, cancers are undoubtedly one of the main 
killers of human beings. In 2014, cancers accounted for about 29.4% of all human 
deaths in Singapore.[1] In fact, Singapore Cancer Registry reported that about one in 
three Singaporeans dies of cancer,[2] and the rates are expected to rise as more people 
live to an old age and becomes more susceptible to cancer. Therefore, it reflects the 
predicament that cancer will remain as a major health problem in Singapore and many 
other countries. The high mortality rate is attributed to the tendency for late diagnoses 
and the lack of effective systemic therapies. Among women, for example, ovarian 
cancer is the leading cause of death from gynaecological cancer,[2] the symptoms of 
which are typically thought not to develop until the disease has progressed to an 
advanced stage whereby the likelihood of cure has diminished significantly. 
 
For the treatment of ovarian cancers, chemotherapy is one of the most common 
treatment options. However, the major challenge to successful chemotherapy is to 
achieve specific drug accumulation at the tumour sites, as most of the currently 
available anticancer agents cannot differentiate between cancerous and healthy cells, 
leading to systemic toxicity and highly undesired side effects. In addition, most of the 
clinically used drugs are of low-molecular weight compounds that exhibit a rather 
short half-life in the body and a high clearance rate, and therefore they diffuse rapidly 
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into healthy tissues and are distributed evenly within the body. 
 
For better diagnosis and effective treatment of cancers, much emphasis has been 
placed on the development of nanocapsules for the encapsulation of both imaging and 
therapeutic agents. Nanocapsules have been widely investigated because they can 
allow for targeted delivery of imaging or therapeutic agents to the cancerous cells 
directly and such site-specific delivery of agents can be primarily achieved through 
either passive or active targeting. Passive targeting involves the preferential accretion 
of nanocarriers at the site of the tumour cells through the enhanced permeability and 
retention effect. Conversely, active targeting entails the affixation of specific targeting 
moiety onto the nanocapsule surface. These surface-functionalized nanocapsules are 
subsequently capable of binding to receptors, which are specific only to the cancerous 
cells. 
 
Indeed, with cell-specific targeting, the systemic toxicity of anticancer drugs will be 
substantially diminished as the biochemical effects of these drugs will be localized to 
the cancerous cells without causing deleterious changes to the surrounding healthy 
tissues. Besides, it will favour an improved delineation of tumours to increase the 
precision of diagnostic images. However, a major setback to the use of nanocapsules 
as delivery vehicles is their susceptibility to the body’s immune system. As these 
nanocapsules are regarded as foreign entities in the body, they will be attacked by 
phagocytes and be eliminated from the body.[3] Therefore, in order to circumvent this 
problem, the biocompatibility of the material used to fabricate the nanocapsule is of 
upmost importance. So far, a multitude of alternatives (e.g. calcium phosphate, gold 
etc.) have been considered, of which silica has proved to be a promising candidate. 
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Silica is bioinert. It experiences little or no chemical changes when exposed to the 
physiological environment. Coupled with the good mechanical stability of silica, this 
ensures that the integrity of the nanocapsule is maintained during its delivery of 
imaging and therapeutic agents to the cancerous cells. Silica is also non-toxic. 
Classified as a biocompatible material, it is safe for usage in the human body. Besides, 
when silica is in its amorphous form, it contains many hydroxyl groups. This will 
impart the silica nanocapsule with a hydrophilic character, which is an essential 
prerequisite as a drug delivery vehicle. This is because most of the anticancer drugs 
and imaging agents (i.e. organic dyes or fluorescent conjugated polymers) are 
hydrophobic in nature, thus by loading them into the interior of the silica 
nanocapsules, these drugs can be safely partitioned from the surrounding aqueous 
blood medium. Meanwhile, the hydrophilic exterior of silica nanocapsules will ensure 
that they remain monodisperse in the bloodstream without clumping together. 
 
Besides, silica nanocapsules can be surface-functionalized through the attachment of 
targeting moieties to the hydroxyl groups of amorphous silica via various silane-
coupling reactions. Hence, active targeting is possible and this will ensure that the 
payloads of silica nanocapsules are solely accumulated at the cancerous cells only. 
Therapeutic efficacy of the anti-cancer drugs can also be potentiated even when using 
relatively low doses of the drugs.[4] Thus, even though nanocapsules have low payload 
capacity due to their small size, this inherent limitation can be circumvented with the 
incorporation of active targeting capabilities. 
 
Lastly, as compared to alternative candidates, the overall cost of silica nanocapsules is 
cheaper than those based on gold[5,6] and has a greater ease of production than calcium 
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phosphate ones.[7,8] Such a plethora of advantages allows silica nanocapsules to be a 
potentially promising candidate for the targeted delivery of imaging and therapeutic 
agents to cancer cells. 
 
The addition of polyethylene glycol (PEG) or polyethylene oxide (PEO) functional 
groups can further enhance the water solubility while minimizing non-specific protein 
adsorption of the silica nanocapsules. Consequently, this would extend the circulation 
time of these silica-based nanocarriers by preventing rapid elimination through the 
body’s reticuloendothelial system, which composes of phagocytic cells (monocytes 
and macrophages) involved in the immune response and are spread throughout the 
body such as the liver and spleen. As a mean to include the PEG/PEO functional 
group to the silica nanocapsules, one can either use commercially available PEO-
based block copolymers (e.g. poloxamers) or perform an organic synthesis to 
incorporate the desired functional group into the chemical structure of the block 
copolymers. Here in this case, poloxamers are tri-block copolymers consisting of 
hydrophilic PEO and hydrophobic polypropylene oxide (PPO) segments arranged in a 
PEO-PPO-PEO structure. Otherwise known by the trade name Pluronic®, they have 
been widely used to direct the formation of the silica shell. 
 
To successfully develop the PEOSNs, I have adopted an interfacial condensation 
scheme, which is an alternative but facile route of synthesis developed by our research 
group, in comparison to some other approaches that have been reported. The silica 
condensation is confined to the interface between the core and corona of polymeric 
micelles while the hydrolysis and condensation reactions are completed under benign 
conditions of the near-neutral pH and at room temperature. Unlike the conventional 
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approach of adding the silica precursor after the polymeric micelles have been 
formed,[9-11] the novelty of our method stems from the fact that the silica precursor and 
PEO-based block copolymer are introduced simultaneously into the aqueous solution. 
Therefore, during the micellization process of amphiphilic block copolymers, the 
silica precursor is first sequestrated into the core of the polymeric micelles. 
 
As a result, the as-synthesized silica nanocapsules are surface-decorated with a layer 
of PEO chains, which enable them to be intrinsically stable in aqueous environments, 
exhibit good antifouling behaviour, have a prolonged blood circulation half-life and 
provide further functionality to which receptor-specific ligands can be attached to.[12] 
This negates the need for further PEGylation, which is an otherwise conventional 
technique to improve the pharmacokinetic properties of silica nanocapsules. Pluronic® 
also inhibits P-glycoprotein efflux pumps to suppress the drug resistance of multi-drug 
resistant cancer cells and enhances the transgene expression when used for gene 
therapy applications.[13,14] Given the desirable properties of Pluronic® for applications 
in various biomedical fields, the block copolymer template is opted to be retained 
after silica shell formation. Therefore, a unique class of robust silica-F127 based 
nanocapsules are developed. 
 
Besides the design of the nanocarrier, another key consideration is the choice of the 
encapsulated payload. Herein, contrast agents that improve the contrast enhancement 
of soft tissues under MRI, are commonly selected for encapsulation. This is because 
the current MRI technology is restricted by its limited ability to differentiate between 
close tissue types. There are two main categories of contrast agents for MRI. T1 
contrast agents are typically paramagnetic complexes such as gadolinium (Gd3+) 
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chelates. They exert positive (bright) contrast which is easier to observe, but there is 
always a risk of high toxicity of the free ions involved. Conversely, T2 contrast agents 
exert negative (dark) contrast on MRI.[15] Currently, superparamagnetic iron oxide 
nanoparticles (SPIONs) are the front-runner for T2 contrast agent. However, there are 
some inherent obstacles to the applications of SPIONs in MRI. For example, there 
may be confusion between the dark contrast of SPIONs with signals from bleeding or 
calcification. In addition, the magnetic susceptibility artefacts associated with these 
magnetic nanoparticles can also distort the background image.[16] 
 
In this regard, MONs represent a new class of MRI contrast agent with many 
favourable characteristics. Besides having positive T1 contrast ability, it is 
antiferromagnetic and does not exert the susceptibility artefacts in MRI. As compared 
to gadolinium-based contrast agents (GBCAs), MONs are also expected to be 
potentially less toxic than their lanthanide counterparts due to the physiological 
function of manganese as a regulatory cofactor for many enzymes and receptors. 








In this PhD project, I propose to develop a class of multifunctional PEOSNs, whereby 
the capabilities of enhanced MRI and fluorescence imaging, stimuli-responsiveness 
and specific targeting are effectively combined into in a single nanocapsular entity. 
Due to the concurrent encapsulation of fluorescence imaging agents and MONs, the 
silica-based nanocapsules will be useful for both optical and MRI imaging. The 
efficiency of these nanocapsules to target specific types of cancer cells and deliver the 
encapsulated payload will be enhanced by developing surface functionalization. In 
addition, it is envisioned that the imaging modality of the nanocapsules can achieve 
selective activation only when in the vicinity of cancerous tissues. This will increase 
the target-to-background signal ratio, thereby improving the sensitivity and specificity 
of cancer detection. 
 
To develop the multifunctional nanocapsules, the interfacial condensation strategy 
will be employed, wherein F127 block copolymers will be employed as the interfacial 
template. Formation of the silica nanoshells will be confined to the interface between 
the core and corona of the F127 micelle, while pre-prepared MONs and fluorescent 
agents will be loaded by the encapsulation of the hydrophobic compounds within the 
micelle core. Meanwhile, in order to improve the targeting efficiency, our strategy is 
to conjugate the nanocapsule surface with specifically designed ligands or functional 
groups that can be recognized by the cells present at the disease site, where the 
specific receptors over-expressed on the cancer cell surface serve as useful targets.  
 
Upon successful establishment of the multifunctional nanocapsules, they will be 
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subsequently investigated for their structures in varying lengthy scales, cell biological 
behaviour (e.g. cell uptaking, antifouling and cytotoxicity), MRI and optical imaging 
properties. Their behaviour, both in vivo and in vitro, will be studied too. 
 
The specific objectives can be summarised as such: 
(i) To develop PEOSNs by employing the interfacial condensation scheme. The 
effects of various key synthesis parameters on the sizes and morphologies of 
PEOSNs will be investigated. In addition, the effectiveness of PEOSNs to 
function as a nanoprobe for bioimaging applications will be established. 
(ii) To incorporate MONs into the PEOSNs for MRI functionality. The synthesis 
conditions required to form highly monodisperse MONs of various sizes will 
be studied. Besides, the feasibility of employing the resultant PEO/SiO2-
coated MONs (PEOMSNs) as T1 MRI contrast agents will be investigated. 
(iii) To construct a class of novel pH-activatable dual modality nanoprobes by 
using the PEOMSNs as a platform material. Folate conjugation to target 
specific types of cancer cells will also be developed. Finally, the efficacy of 
the resultant nanoprobe for the MRI and fluorescence imaging of cancer cells 




Chapter 1 of this thesis establishes the background and motivation of this project, 
which highlights the growing interests in silica-based nanocapsules in bioimaging and 
controlled delivery applications. The basic concept of the interfacial condensation 
scheme to synthesize PEOSNs is established. 
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Chapter 2 summarises the relevant literature regarding the development of MONs as 
MRI contrast agents. The key parameters that influence the paramagnetic relaxation 
enhancement and cytotoxicity of MONs will also be discussed. 
 
Chapter 3 presents a detailed study on the synthesis of PEOSNs, which includes the 
characterisation of their physicochemical properties and optimization of various 
parameters for the nanocarrier development. The ability of PEOSNs to function as an 
effective nanocarrier for bioimaging will also be investigated with zebrafish as the 
vertebrate model. 
 
Chapter 4 details a study on the synthesis of hydrophobic MONs by the thermal 
decomposition of a manganese oleate complex in high boiling hydrocarbon solvents. 
The influence of solvent type, reaction time and reaction temperature on the size and 
size distribution of the resultant MONs is thoroughly investigated. 
 
Chapter 5 discusses the subsequent encapsulation of MONs as the nanocarrier payload 
in PEOSNs. The as-synthesized PEOMSNs will be assessed for their biocompatibility 
and the efficacy as T1 MRI contrast agents using a pre-clinical 7.0 T MRI scanner.   
 
Chapter 6 details the design tenets to engineer PEOMSNs of higher r1 relaxivity. In 
this regard, a hybrid nanoreactor framework is established to prepare hollow MONs 
through a facile acetate buffer solution etching. Modification of the nanoreactor 
architecture is also performed to increase the paramagnetic relaxation enhancement of 
the hollow MONs while the evolution of MnO core morphology with time is studied 
to elucidate the etching mechanism. 
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Chapter 7 reports the detailed synthesis of a pH-activatable dual imaging nanoprobe 
based on the co-encapsulation of MONs and C545T inside a hybrid silica nanoshell. 
The nanoprobes are also conjugated with FA so as to establish a greater affinity for 
cancer cells that over-express FR on their cell membrane. In the hybrid nanosystem, 
the MONs are demonstrated to function as an efficient fluorescence quencher of 
C545T prior to cellular uptake. However, fluorescence recovery is attained upon 
acidic dissolution of the encapsulated MONs following receptor-mediated endocytosis 
into the low pH compartments of the cancer cells. Meanwhile, the Mn2+ ions thus 
released are also shown to exert a strong T1 contrast enhancement in the cancer cells.  
 
Chapter 8 provides a summary of conclusions and the outlook of possible future work 
including the development of pH-activatable dual imaging nanoprobes so as to 
increase their relevance towards cancer diagnosis and gain clinical acceptance for 
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Chapter 2   
LITERATURE REVIEW 
 
2.1 Magnetic Resonance Imaging 
 
MRI is a powerful imaging technique used in clinical diagnosis. It operates by 
measuring the spatial distribution of the water proton signal intensity in the body. 
When the body is subjected to a strong magnetic field during MRI, the protons of 
water molecules in the body will have their magnetic moments align in the direction 
of the magnetic field axis. Due to the torque exerted by the external field, the proton 
magnetic moments will start to precess about the magnetic field axis at an angular  
frequency otherwise known as Larmor precession frequency. Further introduction of a 
radio-frequency (RF) range will cause the precessing spins of these aligned protons to 
be flipped at a resonant frequency. However, disappearance of the RF pulse will cause 
the excited protons to decay back to their original, lower energy spin-down state. This 
energy transition produces a photon which is detected by the detector to generate 
detailed images of the body tissues.[1] 
 
It is noteworthy that apart from the non-invasive acquisition of anatomical images of 
high spatial resolution, MRI does not rely on the usage of radioisotopes or ionizing 
radiation. Therefore, it has been the diagnostic tool of choice to image the central 
nervous system and neurological cancers.[2] However, MRI contrast arises from 
variations in relaxation characteristics of different tissues of interest, which may often 
not be substantial enough to generate an obvious signal contrast in the MR images. 
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Thus, in order to improve lesion delineation and image clarification, MRI contrast 
agents are often administered intravenously in patients. 
 
In the current clinical setting, GBCAs are commonly used. However, due to its recent 
association with nephrogenic systemic fibrosis,[3] there has been an emerging research 
impetus to develop alternative T1 MRI contrast agents that can reduce the risk of 
toxicity, while maintaining a comparable T1 imaging performance to the commercial 
GBCAs. As such, MONs have received great attention in recent years because they 
are expected to be potentially less toxic than its lanthanide counterparts due to the 
physiological function of manganese as a regulatory cofactor for many enzymes and 
receptors.[3] In contrast to the chelated complexes of GBCAs, the nanoparticulate 
features of MONs can also ensure prolonged blood circulation time,[4] thus providing 
a clinically feasible scan time to achieve higher spatial MRI resolution. 
 
Indeed, the in vivo applications of MONs as positive T1 MRI contrast agents have 
been established in preliminary animal studies. For example, formulations of PEG-
phospholipid coated MONs were successfully employed for the anatomical imaging 
of various brain structures in mouse.[5] Nonetheless, as MONs generally remained 
inferior in T1 contrast enhancement as compared to GBCAs, there is an ongoing 
emphasis to develop MONs of higher T1 relaxivity for better diagnostic efficacy. As a 
result, a diverse array of engineered MON-based T1 probes have emerged. Recent 
advances in this field even propose nanoprobe designs which capitalize on the acidic 
dissolution or the in situ reduction of MONs to release Mn2+ ions for a multi-fold 
increase in T1 MRI contrast.[6,7] Thus, there is a need to summarize the current state-
of-the-art for the development of MONs as MRI contrast agents. 
Chapter 2: Literature Review 
 14 
2.2 MON-based MRI contrast agents 
 
For oxides of manganese to function as strong T1 MRI contrast agents, they have to 
contain the divalent manganese (Mn2+) ions, which are characterized by the presence 
of 5 unpaired electrons in their 3d shell. This creates a large magnetic moment and is 
responsible for inducing magnetic relaxation in the nearby nuclei.[2] Comparatively, 
the higher valence states of Mn tend to exhibit less effective T1 relaxation due to 
fewer unpaired electrons and a smaller electron spin relaxation time.[8] As a result, the 
development of manganese-based T1-weighted MRI are primarily focused on the 
MnO or Mn3O4 phase, though there are some exceptions which would be highlighted 
later. Moreover, a nanoparticulate system containing the magnetically active MnO 
component is also preferred due to the high surface concentration of Mn2+ ions. 
Hence, the nanomaterial is able to carry a large paramagnetic payload and exhibit a 
strong T1 contrast enhancement even at a reduced dose. Despite the diverse variety of 
MON-based nanoplatforms, the structure of the nanomaterial system can be broadly 
classified into the following main categories: 
 
2.2.1 Uniformly dispersed MONs in mesoporous framework 
 
For the first class of nanosystem, it is composed of a mesoporous nanomaterial with 
MONs evenly dispersed within. Mesoporous silica nanoparticles (MSNs) are often 
used to form the framework because they allow the dispersed MONs to be easily 
accessible to water molecules, which facilitates their performance as contrast agents. 
For example, Chen and co-workers have synthesized manganese oxide – mesoporous 
silica nanoparticles (Mn-MSNs) using a multistep synthetic strategy.[7,8] In this 
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approach, the MONs were first formed in situ inside the mesopores by the chemical 
reduction of KMnO4 aqueous solution, followed by heat treatment in a reducing 
atmosphere (H2/Ar). In a separate study, Wang et al. used a hydrothermal method to 
produce MONs-capped MSNs,[9] wherein the pre-synthesized water dispersible MONs 
were conjugated to the mesoporous framework via EDC chemistry. 
 
Figure 2.1 Schematic representation for the preparation of manganese oxide dispersed MSNs (Mn-
MSNs). (Adapted from reference [8]) 
 
In general, these MONs-dispersed MSNs could be regarded as a new generation of 
stimuli-responsive MRI contrast agents because the integrated MONs would readily 
disintegrate in response to specific triggers to form free Mn2+ ions, which have a 
significantly higher r1 relativity as compared to its metal oxide counterparts.[10] For 
example, Chen et al. demonstrated that the Mn-MSNs could be activated under mild 
acidic conditions to attain a high r1 relaxivity of 8.81 mM-1s-1.[7] Similarly, Wang et al. 
showed that exposure to a highly reducing environment could cause the dissolution of 
MONs to release free Mn2+ ions for a twofold increase in T1 signal. Such stimuli-
responsive behaviour could be attributed to the absence of a protective coating layer 
for MONs, thereby rendering the exposed nanoparticles to be particularly susceptible 
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to degradation in mild acidic and reduction environment.[7-9] Besides MSNs, graphene 
oxide is an alternative candidate to construct the framework. By using a similar 
double redox strategy as the above,[7,8] Chen et al. successfully dispersed MONs onto 
exfoliated graphene oxide nanosheets.[11] It was reported that the integrated MONs 
could also exhibit both pH-responsive and reduction-triggered T1-weighted MRI, thus 
were highly attractive for stimuli-responsive theranostics. 
 
Nonetheless, there is a possible weakness that can arise from the poor physico-
chemical stability of MONs in the mesoporous framework. Certainly, the integrated 
MONs would release Mn2+ ions upon acidic dissolution or in situ reduction and this 
property could be used for stimuli-responsive dynamic T1-weighted MRI. However, 
chronic exposure to high levels of the Mn2+ ions could lead to an extrapyramidal 
disorder similar to Parkinson’s disease,[12] thereby fostering concern on their clinical 
use. This was also indicated in studies of BxPC-3 cells incubated with MONs-
dispersed MSNs wherein it was also observed that the nanoparticles exhibited no 
cytotoxicity until upon dissolution in a reducing environment to release free Mn2+ 
ions.[9] Nonetheless, to prevent excessive exposure to Mn2+ ions, a possible strategy is 
to confer gate-keeping properties to limit the rate of Mn2+ ion release. For example, 
light-induced switchable rotaxanes can be covalently conjugated to the surface to 
prepare functional MSNs that can be readily modulated by photothermal action.[13] 
 
Another important factor of toxicity lies in the surface properties of the mesoporous 
framework. In this regard, unmodified MSNs, which tend to be negatively charged 
under physiological conditions, have been found to be more cytotoxic than their 
cationically modified counterparts.[14] Pasqua et al. showed that the thiol- or amino-
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functionalization of MSNs was able to reduce the toxicity of MSNs under in vitro 
conditions.[15] Yildirim et al. also indicated that the haemolytic activity of MSNs have 
been significantly reduced by their functionalization with organosilane monomers.[16] 
This improves the blood compatibility of MSNs, which is an important aspect to be 
considered for the intravenous injection of nanoparticles as MRI contrast agents. Most 
reported syntheses of MSNs also employ structure-directing agents to generate the 
mesopores. Herein, the biocompatibility of structure-directing agents is important to 
minimize particle-induced toxicity. On this topic, interested readers are recommended 
to consult some of the excellent review covering the different approaches to MSN 
syntheses.[14] 
 
2.2.2 Core-shell structured MONs 
 
Metabolomics analyses have indicated that in vivo exposure to uncoated MONs could 
lead to the disturbances of a number of metabolic processes in the organism and 
induce hepatic necrosis to a certain extent.[17] Hence, the second category of 
nanostructure involved the traditional coating of a biocompatible layer onto the 
surface of MONs to form a core-shell configuration. For this class of nanosystem, 
newly-prepared MONs are typically used as a hard template for the subsequent 
coating of the shell material. This approach is advantageous because the organic 
synthesis of metal oxide nanoparticles to precisely control their shape and size 
distribution is well-established.[18] Therefore, it ensures that the resultant MONs are 
monodisperse and offer an avenue to tailor the magnetic properties of MONs for 
higher r1 relaxivity. 
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However, due to the inherent hydrophobicity upon synthesis in organic solvents, it 
also implies that the coating materials ought to render the MONs water-dispersible 
and colloidally stable in the physiological environment. To this extent, the covalent 
attachment of PEG chains to the coating layer is a popular strategy to improve the 
aqueous solubility of MONs. In particular, Gallo et al. reported that the longer PEG 
molecules (~ 5000 Da) were preferred for nanoparticle functionalization because they 
prolonged the blood circulation time of MONs and afforded a greater accumulation in 
tumours.[19] More importantly, the coating material should also allow the encapsulated 
manganese paramagnetic core to interact readily with the surrounding water molecules 
for a higher r1 relaxivity. For instance, despite the excellent biocompatibility of 
nanostructured silica, it has been argued that the r1 relaxivity of silica-coated MONs is 
inevitably affected by the dense coating layer, which reduces the accessibility of water 
molecules to the MnO core.[20] 
 
Figure 2.2 Schematic representation for the preparation of MnO@SiO2 core-shell nanoparticles. 
(Adapted from reference [46]) 
 
Opsonisation is an immune process by which foreign entities in the body are adsorbed 
with plasma proteins (opsonins) to render them more visible to phagocytic cells for 
rapid clearance from the bloodstream. In this regard, the coating material should also 
be sufficiently thin so that the overall diameter remains less than 100 nm. Such 
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dimension would favour the reduced opsonisation of MONs so that the signal duration 
is sufficiently long for in vivo MR contrast enhancement. 
 
From a toxicological standpoint, the coating material should be stable enough, both 
during storage and under in vivo conditions because for core-shell structured MONs, 
compromise of the coating layer can reveal the metal oxide core, which is toxic upon 
dissolution to its constituent metal ions (Mn2+). This would preclude the use of 
numerous amphiphilic polymers as the coating material due to the inherent instability 
of the polymeric micelles at concentrations below the critical micelle concentration of 
the polymer. Nonetheless, such limitations can be overcome by developing shell 
cross-linkable micelles that do not readily disintegrate into its different constituents in 
the physiological environment. 
 
Finally, cytotoxicity of the coating material itself is a major determining factor in the 
overall toxicity of MONs. To this extent, we propose the classification of core-shell 
structured MONs based on the type of nanoparticle coatings, which will be elaborated 
in a later section. These properties have to be considered alongside with improving the 
r1 relaxivity of MONs so as to develop safe nanoprobes of excellent contrast ability 
for practical clinical MRI applications. 
 
2.2.3 Redoxable MnO2 nanosheets 
 
Recently, MnO2 nanosheets have been proposed for use as T1 MRI contrast agents. 
However, unlike the previous classes of MON-based nanoplatforms, MnO2 
nanosheets per se tend to exhibit very low r1 relaxivity. This is due to the fewer 
unpaired electrons in the d3 configuration of Mn4+ ions. Correspondingly, the electron 
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spin magnetic moment of Mn4+ ions is smaller and unable to accelerate the 
longitudinal relaxation of water protons as effectively.[21] Instead, the MnO2 
nanosheets are uniquely designed to be intracellular glutathione (GSH)-activated MRI 
contrast agents.[22,23] Herein, GSH is a cytosolic biomolecule which is often present in 
elevated levels in cancerous tissues. As a reducing agent, GSH could also induce the 
dissolution of MnO2 nanosheets to release Mn2+ ions for MRI contrast enhancement. 
 
Figure 2.3 Schematic representation of MnO2-nanosheet-modified upconversion nanoparticles for 
intracellular GSH detection. (Adapted from reference [22]) 
 
It is noteworthy that these MnO2 nanosheets could also be coupled to lanthanide-
doped upconversion nanoparticles[22] or cyanine dyes[23] to incorporate fluorescence-
activatable properties for cancer diagnostics applications. For such nanocomposite 
probe designs, the MnO2 nanosheets would serve to quench the fluorophores 
effectively. However, upon cellular uptake by the targeted cancer cells, they would be 
reduced by the intracellular GSH, thus leading to fluorescence restoration of the 
nanoprobe. 
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However, there are concerns about the biocompatibility of MnO2 nanosheets despite 
their novel stimuli-responsive MRI behaviour. Studies have suggested that the MnO2 
nanomaterial could induce significant accumulation of reactive oxygen species and 
result in the formation of oxidative stress in cells.[24] Hence, this would lead to DNA 
oxidative damage-induced necrosis and cell apoptosis. Yet, in the experimental 
designs of MnO2 nanosheets for T1-weighted MRI,[22,23] the MONs are typically not 
assigned with biocompatible secondary coatings to mitigate their risk of nanotoxicity, 
which is exacerbated by a lack of toxicology-based studies for this newly-developed 
nanosystem. Therefore, special attention should be given to determine the absorption, 
distribution, metabolism and excretion (ADME) characteristics of the released free 
Mn2+ ions from the nanosheets. 
 
2.2.4 MON-based heterodimer nanocomposites 
 
The feasibility of developing MON as hetero-nanoparticles has been demonstrated by 
various groups. Touted as the next generation Janus-type nanoparticles, it is 
envisioned that such nanocomposites would be highly versatile for applications in 
biomedical imaging due to their multifunctional capabilities. For instance, Im et al. 
reported the synthesis of a T1-T2 dual modal MRI contrast agent based on Fe3O4/MnO 
hybrid nanocrystals.[25] Schladt et al. successfully constructed Au@MnO nanoflowers 
for concurrent magnetic and optical detection.[26] For these works, formation of the 
hetero-nanoparticles is achieved by a heterogeneous nucleation of MONs onto the 
surface of the other inorganic/metallic counterpart (e.g. Fe3O4 or Au nanocrystals). As 
a result, the two inorganic domains are joined together through a small interfacial area 
to form an asymmetric structure with different regions of surface-active properties.  
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Interestingly, it has been reported that a synergistic enhancement in the nanoscale 
properties could be achieved in anisotropic gold and metal oxide nanoparticles (e.g. 
Au@MnO heterodimer). Unlike the isotropic analogues with a uniform wettability, 
these Janus-type nanoparticles would exhibit an amphiphilic character, thereby 
favouring their self-assembly at the oil-water interface due to the drastic decrease in 
interfacial tension.[27] Moreover, selective surface functionalization could also be 
achieved, as Schick et al. successfully encapsulated the metal oxide domain with a 
silica coating while leaving the gold domain untouched.[28] 
 
Figure 2.4 (a) Schematic representation of a functionalized Au@MnO nanoflower with selective 
attachment of catechol anchors to metal oxide petals and thiol anchors to the gold core. (b) TEM image 
of polymer-coated Au@MnO nanoflower. (Adapted from reference [26]) 
 
Generally, cell viability assays have suggested the non-cytotoxic nature of MON-
based heterodimers.[26,28] Nevertheless, comparison between these studies can be 
somewhat difficult due to the lack of uniformity in the methods used to assess toxicity 
and the vastly different physicochemical properties of individual compounds. Besides, 
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the introduction of multiple inorganic nanoparticles as part of the hetero-structure 
would also increase the complexity of cytotoxicity assessment since dissolution of 
either inorganic core to their constituent metal ions could increase the potential 
toxicity risks. As established in core-structured MONs, the toxicity risks of these 
nanocomposites are also strongly influenced by the type of the coating material used. 
This is because their syntheses are typically achieved by non-hydrolytic routes, thus a 
suitable ligand or shell coating is required to improve their aqueous dispersibility. 
 
2.3 Paramagnetic Relaxation Enhancement of MONs 
 
It is noteworthy that MRI is increasingly moving to higher fields (1.5 T and above), 
which bring about greater signal-to-noise ratio and its attendant benefits of higher 
spatial resolution and/or reduced acquisition time. Yet, the r1 relaxivity of MRI 
contrast agents typically decreases at higher field strength. For example, Kim and co-
workers have reported that the r1 value of mesoporous silica-coated hollow MONs 
decreases from 1.72 mM-1s-1 at 1.5 T to 0.99 mM-1s-1 at 11.7 T.[20] This is attributed to 
the increased magnetization of paramagnetic MONs at higher magnetic fields, which 
favours the domination of T2 effects and a reduced effectiveness of MONs to shorten 
the T1 relaxation time of water.[29] Therefore, it highlights the need to develop MON-
based contrast agents of higher relaxivities. Moreover, in lieu of the direct dose-
dependent relationship on the contrast enhancement effect, a higher r1 relaxivity is 
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To increase the r1 relaxivity of MONs, current strategies are largely targeted towards 
improving the interaction of water molecules and the magnetic core. Given that only 
the surface Mn2+ ions of the nanoparticle are mainly responsible for the longitudinal 
water proton relaxation, a larger surface-to-volume ratio of MONs is expected to 
favour a more efficient rate of water exchange. In fact, several research groups have 
supported this hypothesis. For example, amongst the different nanostructured 
morphologies of MONs, nanoplates were observed to exhibit the highest r1 relaxivity 
due to their largest surface areas.[30] Na et al. also demonstrated that the T1-weighted 
MR images of MONs were considerably brighter as the particle size decreased.[5] 
Likewise, the formation of hollow MONs is another popular approach to improve the 
particle surface-to-volume ratio. This is usually achieved by employing a suitable 
etchant (e.g. phthalate buffer,[31] mild hydrochloric acid[20] or hydroxylamine 
solution[32]) to selectively remove the MnO core from a sacrificial template of MnO-
Mn3O4 core-shell nanoparticles. 
 
For core-shell structured MONs, the interaction of MONs with water molecules is 
also strongly dependent on the level of porosity in the coating material, thus structural 
modifications of the coating layer can be performed to enhance its water permeability. 
For instance, Peng et al. verified that a higher silica shell porosity would yield a larger 
r1 relaxivity due to the improved accessibility of water molecules to the encapsulated 
MONs.[33] To generate the mesopores in the silica shell, an organic structure-directing 
template such as cetyltrimethylammonium bromide is typically used.[20,33] Besides, the 
hydrophilicity of polymer ligands is an important prerequisite too, owning to a more 
efficient water exchange exerted by the MONs. Xing et al. synthesized polyaspartic 
acid coated MONs that were demonstrated with an r1 relaxivity of 1.29 mM-1s-1.[34] In 
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contrast, using the comparatively more hydrophobic poly(lactic-co-glycolic acid) as a 
coating material resulted in a lower r1 relaxivity of 0.21 mM-1s-1 for the MONs.[10] 
 
For nanoprobe designs (e.g. redoxable MnO2 nanosheets) which rely on the release of 
Mn2+ ions for T1 MRI contrast enhancement, the rotational correlation time of the free 
ions should be modulated such that it corresponds closely to the proton Larmor 
precession frequency. This ensures that the spin-lattice relaxation is more efficient and 
a higher r1 relaxivity can be attained. In this regard, Caravan and co-workers showed 
that the paramagnetic relaxation could be optimized by a protein binding strategy to 
reduce the rotational correlation time of T1 contrast agents.[29] For instance, the r1 
value of MnL1 complex was shown to increase from 4.46 mM-1s-1 (unbound form) to 
5.78 mM-1s-1 (protein-bound form) at 4.7 T. Similar studies have also suggested that 
dendrimer conjugation was another viable approach to favour a slower rotational 
correlation time for higher r1 relaxivity.[35] 
 
Indeed, the influence of rotational dynamics is a useful parameter to optimize the r1 
relaxivity, especially at low fields. Nonetheless, it is not without accompanying 
drawbacks. For example, there are concerns that the binding of proteins (e.g. human 
serum albumin) could reduce the colloidal stability, thereby increasing their tendency 
to precipitate upon prolonged storage.[36] 
 
2.4 Cytotoxicity of MONs 
 
Due to the wide variety of functionalities and physicochemical properties of MONs, 
there is a lack of consensus on the toxicological properties of MONs. It is in this 
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context that an understanding of the toxicological properties of MONs is essential 
prior to their clinical translation. 
 
Toxicity of MONs can be induced by several mechanisms including the production of 
reactive oxygen species and the nanoparticle degradation leading to an excessive 
accumulation of Mn2+ ions. Table 2.1 is a summary of the studies performed to 
determine the potential toxicity of MONs or lack thereof. It is evident that in vitro 
examination accounts for majority of the nanotoxicological research. Indeed, these in 
vitro assays can be used to screen hazardous nanomaterials and provide useful 
mechanistic insights about the nano-bio interactions. For example, MONs-dispersed 
MSNs were shown to exhibit a half-maximal inhibitory concentration (IC50) of 
400μg/mL in breast cancer MCF-7 cells after 36-hours incubation.[8] Meanwhile, it 
was revealed that the high intracellular GSH concentration of cancer cells was 
sufficient to trigger the steady dissolution of Mn3O4 nanocrystals via a thiol-disulfide 
transformation to produce Mn2+ ions.[9] 
 
Nonetheless, given the variability in cell lines and a wide range of nanoparticle 
concentration used to evaluate the nanotoxicity of MONs, comparability of the in vitro 
studies may be open to doubt due to the lack of test procedure standardization. Often, 
the problem is complicated further by insufficient characterization of the investigated 
nanomaterial.[37] Hence, in the following section, we would discuss the key 
parameters that influence the cytotoxicity of MONs, which are essentially dependent 
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2.4.1 Composition of nanocarrier 
 
From a toxicological perspective, the coating material should be stable enough, both 
during storage and under in vivo conditions in order to prevent Mn-ion leaching and 
avoid toxic accumulation of Mn2+ in tissues. These properties have to be considered 
alongside with improving the r1 relaxivity of MONs so as to develop safe nanoprobes 
of excellent contrast ability for practical clinical MRI applications. In general, there 
are four main classifications for the coating layers of MONs. 
 
2.4.1.1 PEG-phospholipid micelles 
 
In the seminal publication first describing the use of MONs as T1 contrast agents for 
MRI, Na et al. employed PEG-phospholipid micelles to encapsulate MONs.[5] The 
potential toxicity of these PEG-phospholipid coated MONs was subsequently 
investigated in eight different cell lines. It was observed that the IC50 value could 
range from 0.36 mM of Mn in NCI-H460 cells to 4.73 mM of Mn in MRC-5 cells. 
Inductive coupled plasma-atomic emission spectroscopy (ICP-AES) also suggested no 
appreciable Mn-ion leaching from the MONs when kept for 7 days at room 
temperature while their in vivo biocompatibility was indicated by an absence of 
abnormal behavioural changes or signs of weight loss in mice that were injected with 
the PEG-phospholipid coated MONs. 
 
Shin et al. extended the system to encapsulate hollow MONs, which were reported to 
be relatively non-cytotoxic to MCF-7 cell lines after 72 hours.[31] Similarly, Howell et 
al. encapsulated MONs with a phospholipid shell (DC-cholesterol and DOPE) 
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surface-decorated with an outer corona of PEG polymers.[38] In vitro cytotoxicity was 
evaluated in HEK293 cells using the Presto Blue assay and the results showed no 
apparent toxicity of the nanoparticles after 72 hours at a concentration of 14 μg/mL. 
 
Figure 2.5 TEM images of PEG-phospholipid coated MONs with particle sizes of 7, 15, 20 and 25 nm. 
(Adapted from reference [5]) 
 
Therefore, these in vitro studies suggest that PEG-phospholipid is generally useful to 
render the MONs biologically compatible due to the lack of observable cytotoxicity of 
MONs to the various human cell lines (normal and cancer). There was also no 
apparent MON-induced toxicity in mice in vivo. These findings could be attributed to 
the tight hydrophobic inner layer of the phospholipid micelles, which forms a strong 
protective barrier for the as-encapsulated MONs. Herein lies both the benefit and 
drawback: although the PEG-phospholipid coating enhances the physicochemical 
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stability of MONs and significantly reduces the likelihood of Mn-ion leaching under 
oxidative conditions,[5] it also prevents direct water interaction with the encapsulated 
MON which is otherwise required for efficient water exchange.[34] Consequently, the 
r1 relaxivity of PEG-phospholipid coated MONs tends to be inherently low. 
 
2.4.1.2 Silica shell 
 
The second class of coating material involves a nanostructured silica shell. While it 
may be difficult to alter the phospholipid structure without interfering with the 
micellar stability, the silica coating is advantageous in that it can be facilely modified 
by structural engineering techniques (e.g. generation of mesopores) to improve the r1 
relaxivity.[20] 
 
Cytotoxicity studies generally demonstrate that as a “capping” material, silica shell 
has excellent biocompatibility and pose no adverse effect on cell viability. For 
example, Hu et al. encapsulated MONs within an amino-functionalized silica shell 
surface-conjugated with PEG chains.[39] Based on a MTT assay with HeLa and L02 
cells, it was indicated that the nanoparticles had minimal cytotoxicity since a high cell 
viability of over 90% was maintained for 24 hours even at high nanoparticle 
concentration of 1000 μg/mL. Similar findings were also reported by Yang et al. who 
developed silica coated MONs surface-modified with PEG and FA.[40] From these 
studies, it shows that the nanostructured silica shell architecture is functioning as a 
biocompatible nanoplatform to overcome the inherent toxicity and poor water 
solubility of MONs under physiological conditions.[41] 
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Moreover, the silica coating also increases the resistance of MONs to degradation, 
thus it is effective to prevent Mn-ion leaching. In fact, Lee and co-workers have 
reported that amongst the various coatings tested for core-shell structured MONs, a 
silica coating layer is most effective to reduce the likelihood of Mn-ion leaching.[42]  
 
 
Figure 2.6 TEM images of MONs coated with a uniform shell of: (a) mesoporous silica; and (b) dense 
silica prepared by a w/o reverse microemulsion technique. (Adapted from reference [33, 46]) 
 
Mice toxicity studies were also carried out by Hu et al where samples of major organs 
were taken at 10 days post-injection for histological examination.[39] There were no 
indications that the nanoparticles caused any adverse effects in the animals as no 
apparent cellular or tissue damage was observed in any of the organs examined. There 
was also no inflammatory response as seen in blood smears while kidney and hepatic 
function indicators were at the same levels as controls, thereby affirming the non-
cytotoxic nature of silica coated MONs. 
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2.4.1.3 Dopamine-based ligands 
 
Biocompatible ligands conjugated with dopamine moieties are an alternative class of 
coating materials to functionalize MONs for applications as T1 MRI contrast agents. 
This coating strategy has received surging interests among the scientific community 
because dopamine has proven to be a unique catechol anchor group that has a strong 
binding affinity to metal oxide nanoparticles.[43] Schladt et al. synthesized highly 
water-dispersible MONs by employing a dopamine-PEG-protoporphyrin (DA-PEG-
PP) ligand.[44] MTT assay of the DA-PEG-PP functionalized MONs indicated a low 
level of cytotoxicity as high cell viability of over 90 % was observed after 48 hour 
incubation at a concentration of 100 μg/mL. Shukoor et al. also immobilized ssDNA 
(CpG ODN 2006) onto MONs by using a dopamine-based polymeric ligand with a 
reactive amine group for the coupling of ssDNA.[45] It was reported that the 
nanoparticles were relatively non-toxic for concentrations up to 50 μg/mL. 
 
 
Figure 2.7 (a) Chemical structure of a multifunctional copolymer containing dopamine (DA) as an 
anchor group for the binding of metal oxides, a free amine group for the conjugation of biomolecules, 
and rhodamine as a fluorophore. (b) Functionalization of MONs using DA-PEG-PP ligand for 
photodynamic therapy of cancer cells. (Adapted from reference [44, 45]) 
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Indeed, dopamine has been commonly conjugated to biocompatible polymers or 
proteins so as to immobilize these functional molecules onto MONs.[36,44,45] However, 
it has also been reported the catechol unit in dopamine tends to oxidize under aerobic 
conditions to form dark insoluble polymers,[43] thereby affecting the binding stability 
between dopamine and the metal oxide surface. As a result, the dopamine-based 
ligand coating may be labile and degrading in water and biological fluids, thus 
exposing the MON core complex to dissolution. This was verified by Schladt et al., 
who demonstrated the susceptibility of DA-PEG coated MONs to Mn-ion leaching 
because transmission electron microscopy (TEM) images of the MONs had appeared 
rougher and less homogeneous after the leaching experiments.[46] 
 
2.4.1.4 Polymer ligands 
 
A number of in vitro and in vivo studies have been conducted to assess the toxicity of 
MONs stabilized by polymeric ligands. For example, Gallo et al. displaced the oleic 
acid surface ligands of MONs with 1-aminoundecanoic acid, followed by PEG 
coupling for better biocompatibility.[19] In vitro toxicity experiments indicated an IC50 
value of 0.14 mM of Mn for these functionalised nanoparticles, which was a higher 
level than what was required for imaging in vivo. Meanwhile, Huang et al. employed 
polystyrene sulfonate polymer to replace the hydrophobic surfactants of the MONs.[32] 
A MTT assay revealed that the cell viability remained high (> 90%) even at a high Mn 
concentration of 1.3 mM for 1 day. The negatively charged polymeric coating was 
also effective in preventing Mn-ion leaching as ICP-AES analysis indicates that only a 
very small amount of free Mn2+ ions (~1.3%) was produced upon incubation in 
phosphate buffered saline (PBS) solution at 37°C for 48 hours. 
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From these studies, it can be seen that engineered MONs with polymeric ligand can 
have vastly different outer coating bioactivity, depending on the type of polymers 
used. Hence, each type of MONs in this classification should be characterized 
individually for its potential toxicity and ADME characteristics. Nonetheless, based 
on the Pearson acid base (HSAB) concept, oxygen containing polymers would be 
particularly favoured because they can exhibit a high binding affinity to MONs.[43] As 
a result, a compact coating layer is achieved for highly effective water-manganese 
interactions. 
 
2.4.2 Size and shape of MON core 
 
The effect on the r1 relaxivity by changing the particle size and shape of MONs has 
been well-established. However, the interplay between MON morphology and toxicity 
is less commonly discussed. Firstly, given that smaller nanoparticles have a larger 
surface-to-volume ratio and higher surface reactivity, it is likely that smaller sized 
MONs are potentially more cytotoxic due to their greater susceptibility to Mn-ion 
leaching. Moreover, they would be more prone to aggregation, especially in the 
presence of serum proteins in the cell culture medium. Such instability in the cell 
medium would affect the cellular uptake of MONs during in vitro assays and alter the 
toxicological profile of MONs accordingly. 
 
Secondly, based on studies on other inorganic nanoparticles, it was observed that 
transferrin-coated rod-shaped gold nanoparticles were less readily internalized by 
HeLa cells as compared to their spherical counterparts.[47] As a result, conclusions 
about the toxic potential of the nanoparticles would be misleading since the high cell 
Chapter 2: Literature Review 
 36 
viability arose from a decreased cellular uptake of nanoparticles instead of an 
improved biocompatibility of the nanoparticles. Interestingly, it has also been shown 
that for TiO2 nanoparticles with high aspect ratios, they may cause shape-induced 
toxicity by lysosomal disruption.[48] Certainly, the nano-bio interactions of MONs 
with varying shapes may be different, nonetheless it highlights the importance of 
elucidating the potential impact of particle shape on the cytotoxicity assessment of 
MONs. 
 
2.5 Pharmacokinetics of MONs 
 
Examining the cytotoxicity of MONs alone is inadequate for the risk assessment of 
MONs as T1 MRI contrast agents for clinical use. It is also crucial to understand the 
ADME characteristics of MONs in the living system. This will enable one to discern 
how long the nanoparticles will be present within the body, as well as to predict the 
organs or tissues in which they distribute. In this regard, the following section seeks to 
consider several key parameters for an assessment of the in vivo nanotoxicological 
profile of MONs. 
 
2.5.1 Opsonisation and blood circulation time 
 
While there has been one instance of the intranasal administration of MONs in the 
form of nasal drops,[38] most in vivo studies involve an intravenous injection of 
MONs. Therefore, the absorption is fairly straightforward and bioavailability is often 
near 100% since the administered dose of MONs is directly introduced into the 
systemic circulation. However, one of the most critical issues associated with the 
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intravenous route of administration is the possible binding of opsonins to the 
nanoparticles which can facilitate their capture by macrophages in the bloodstream.[43] 
This is a major obstacle because it reduces the blood circulation time of MONs and 
prevents a clinically feasible scan time for high spatial MRI resolution.  
 
The degree of opsonisation is affected by the overall size of nanoparticles. Larger 
nanoparticles (> 200 nm) tend to be quickly recognized and eliminated by the 
reticuloendothelial system. In this regard, one significant challenge of using MSNs as 
a platform to disperse MONs lies in the large size of the mesoporous framework, 
which typically ranges in the order of several hundreds of nm.[14] Chen et al. 
investigated the biodistribution of Mn-MSNs injected into mice,[8] which was 
observed to rapidly accumulate in the liver and spleen; such enhanced uptake 
suggested that the nanoparticles were highly susceptible to splenic filtration and be 
removed from circulation in the blood. 
 
Comparatively, the hydrodynamic size of core-shell structured MONs is usually 
smaller to avoid fast reticuloendothelial system uptake, yet large enough to be above 
the renal clearance threshold of 5.5 nm. Hence, they are more suited for long 
circulation nanoparticle formulation and can be used to achieve site-specific 
accumulation in designated areas such as tumours. For example, Hu et al. 
demonstrated the ability of silica-coated MONs to function as tumour-specific MRI 
contrast agents by determining their quantitative biodistribution in tumour-bearing 
mice.[39] The majority of the nanoparticles were seen to accumulate in the tumour, 
with smaller amount taken up in the liver and spleen. 
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The likelihood of opsonisation is also strongly correlated to the length of PEG 
molecules conjugated to MONs. Gallo et al. investigated the bioaccumulation of 
PEGylated MONs in the liver, spleen and gall bladder by analysing the Mn content of 
the various tissues harvested from mice.[19] It was revealed that nanoparticles which 
were functionalised with longer PEG chains (5000 Da) exhibited a greater degree of 
accumulation at longer time duration than that of their shorter PEG counterparts (600 
Da). This indicates that having a longer PEG length is effective to prevent adsorption 
of serum proteins, hence prolonging the blood circulation of MONs before their 
eventual uptake into the liver and spleen. 
 
2.5.2 Biodistribution and clearance 
 
Several in vivo studies have suggested that the biodistribution of core-shell structured 
MONs are fairly similar despite the variation in coating material used. Howell et al. 
indicated that the highest accumulation of PEG-phospholipid coated MONs was 
detected in the liver after 24 hours post-injection.[38] Yang et al., who traced the fate of 
silica-coated MONs in mice 4 hours post-injection, also reported similar 
observations.[40] Such findings can be attributed to the thickness of the coating 
material, which necessarily increase the hydrodynamic diameter. Dense PEGylation 
might increase the blood half-life, but it also increases the hydrodynamic diameter 
beyond the renal filtration threshold and precludes renal excretion from the body. 
Hence, despite the systemic circulation of the nanoparticles to all bodily organs, the 
liver is observed to be the target organ of higher nanoparticle accumulation.  
 
Nonetheless, discrepancies in the literature exist. For example, Chevallier et al. 
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reported the presence of low Mn content in the liver and spleen by neutron activation 
analysis.[49] Instead, the PEGylated MONs were found to accumulate primarily in the 
faeces, intestine, gall bladder, kidneys and stomach, in the decreasing order of 
magnitude. This suggests that the uptake of nanoparticles by the reticuloendothelial 
system is relatively negligible. Such atypical biodistribution data was attributed to the 
ultra small dimensions of MONs (6-8 nm diameter), which were also grafted with 
highly hydrophilic PEGylated bis-phosphonate dendrons (PDn) for the smallest 
possible hydrodynamic diameter. Moreover, it was demonstrated that over 70% of the 
injected dose was eliminated from the body within 48 hours as PDn grafting could be 
applied advantageously to confer fast renal clearance of the MONs. 
 
As has been identified in several in vivo studies, the liver is likely the main organ for 
the clearance of nanoparticles from the blood circulation. For example, the 
concentration of silica-coated MONs in the liver of mice was observed to peak at 12 
hour post-injection before decreasing considerably by the 24-hour time point.[39] 
Howell et al. also reported that the highest accumulation of PEG-phospholipid coated 
MONs was detected in the liver after 24 hours, before declining significantly to the 
control levels by the 96 hour time point.[38] 
 
To account for a possible route of excretion in the liver, a distinction should first be 
made between the two major cell types of the liver: the Kupffer cells and the 
hepatocytes. Due to the particulate nature of MONs, they are likely to be engulfed by 
the Kupffer cells of the liver, which forms part of the reticuloendothelial system. This 
is usually undesirable as the phagocytized material is expected to remain in the body 
for a long period of time and increases the likelihood of toxicity. However, once in the 
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Kupffer cells, the nanoparticles would be shuttled to the low pH compartments (acidic 
endosomes) within the cells. This results in the dissolution of MONs to release Mn2+ 
ions, which could subsequently be taken up by the adjacent hepatocytes and be 
excreted through the biliary pathway. Hence, the MONs are unlikely to present 
problems with body burdens, as verified by the absence of MONs accumulation in the 
liver at longer periods of times. 
 
2.5.3 Interaction with blood components 
 
Upon entry into the body, the intravenously injected MONs would interact with the 
various blood components including the red blood cells and platelets. Therefore, from 
a toxicological perspective, the MONs should not compromise the red blood cell 
membrane and induce the rupture of red blood cells. Otherwise, the leakage of 
haemoglobin could potentially lead to adverse health effects such as anaemia or 
hypohepatia. In vitro haemolysis assay indicated that the haemolysis potential of 
MONs was 2.85%.[50] This is less than the 5% limit criterion in ASTM E2524-08, 
which is the standard test method to analyze haemolytic properties of nanoparticles. 
Hence, it indicates that the water-dispersible MONs exhibit good haemocompatibility. 
 
Another important consideration for the toxicity profile of MONs is the particle 
susceptibility to trigger the inflammatory response in the body. Herein, by measuring 
the secretion levels of inflammatory cytokines such as interleukin 12, Schladt et al 
quantified that silica-coated MONs were not able to activate the inflammatory bone 
marrow-derived dendritic cells.[46] This indicated that the injected MONs would not 
exert any toxic effect in cells. 




The development of MONs as T1 MRI contrast agents is a burgeoning field of 
research with huge prospects for medical imaging applications. Herein, the studies 
reviewed in the present work suggest several key points: 
 
(1) To achieve higher r1 relaxivities of MONs, current strategies include increasing the 
surface-to-volume ratio of MONs and the water permeability of the nanocarrier, as 
well as an optimization of the rotational correlation time of the paramagnetic payload. 
 
(2) The nanotoxicity profile and ADME characteristics of MONs are dependent on the 
structure of the nanomaterial system and the type of coating materials used. To 
optimize the nanotoxicity evaluation of MONs, it is also necessary to characterize the 
key material properties so as to increase the significance of the studies. 
 
Therefore, these core tenets will serve to guide in the rationale design of the pH-
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For the past decade, surface-decorated silica nanocapsules have emerged as one of the 
most promising candidates for nanocarriers in biomedical fields for cellular imaging, 
diagnosis and controlled delivery, as shown by their capabilities of encapsulating 
various functional inorganic nanoparticles, imaging tags and therapeutic payloads.[1-17] 
They are more stable in structure than conventional polymer-based nanocarriers18 
while their excellent biocompatibility is affirmed by the classification of silica as 
“generally recognized as safe” (GRAS) by the US Food and Drug Administration.[19] 
Indeed, surface-decorated silica nanocapsules are commonly used for specific cellular 
targeting, where both in vitro as well as in vivo experiments have been conducted.[4-
10,15-16] 
 
In order to prepare surface-decorated silica nanocapsules for biomedical applications, 
several different types of template-assisted approaches have been adopted. These 
templates can be broadly classified into two major categories: hard and soft templates. 
Hard (solid) templates include iron oxide nanocrystals,[1-6] monodispersed silica[7-9] or 
even gold nanoparticles[10-11] while soft templates comprise primarily of 
microemulsion droplets[13-16] and polymeric micelles.[20-23] Despite the considerable 
differences in the detailed synthesis procedures, these template-assisted approaches 
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usually consist of four major processing steps: (i) preparation of an appropriate 
template; (ii) formation of an outer silica shell on the template surface through 
controlled chemical precipitation of silica precursors in the solution; (iii) template 
removal to generate the desired hollow structure; and (iv) surface decoration by 
introducing appropriate functional groups through chemical reaction. 
 
In the hard templating techniques, removal of the template typically involves 
calcination at high temperatures[2,6] or immersion in a strongly acidic 
environment,[1,4,10] both of which are potentially detrimental to biologically active 
compounds.[24] Consequently, this technique does not offer the option of an in situ 
encapsulation of the functional molecules during the synthesis of silica nanocapsules. 
To overcome such a drawback, there have been considerable progresses with the soft 
templating techniques, which usually involve a more gentle template removal process 
at room temperature and with milder solvents such as ethanol. 
 
For example, several researchers have employed microemulsion droplets, which 
contained the functional molecules, as the template for silica shell formation.[13-16] 
Nonetheless, due to droplet coalescence during the synthesis process,[24] the resultant 
silica nanocapsules tend to exhibit a large overall size with diameter > 200 nm.[13] 
This reduces their blood circulation time, because of an increased susceptibility to 
rapid splenic uptake.[25] Besides, certain surfactants such as cetyltrimethylammonium 
bromide, which is commonly used to stabilize the oil/water interface in the 
microemulsion system,[15] is highly toxic and the incomplete removal can impede the 
use of silica nanocapsules for biomedical applications. 
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Polymeric micelles can function simultaneously as both an encapsulant and soft 
templating agent too.[20-23] Polymeric micelle-templated silica nanocapsules typically 
ranges from 50 – 100 nm, which is an ideal dimension for the prolonged blood 
circulation and enhanced level of drug delivery.[25] For example, non-ionic PEO-based 
block copolymers have been used as a templating agent due to their good affinity with 
silica.[21,22] However, a highly acidic environment is typically employed to protonate 
the PEO segments so that silica precursors can be readily adsorbed onto them through 
electrostatic interactions. Such harsh synthesis conditions would preclude the in situ 
encapsulation of many pH-sensitive compounds (e.g. iron oxide nanocrystals and 
DNA molecules). This limits the versatility of silica nanocapsules as nanocarriers for 
biomedical applications. 
 
Therefore, particular emphasis has been placed on the development of synthesis 
methodologies to fabricate silica nanocapsules under benign conditions. Yuan and 
coworkers, for example, demonstrated one of such methods by synthesizing cationic 
block copolymers that were able not only to confine silica shell formation, but also 
catalyze the hydrolysis and condensation of silica precursors at neutral pH and room 
temperature.[26] Nevertheless, the procedure involved several organic synthesis steps 
and therefore careful control was needed in order to develop the most desirable 
nanohollow structure. It is in this context that our group have developed an interfacial 
condensation scheme to fabricate the PEOSNs.[27] 
 
Herein, in the present study, the sizes and morphologies of PEOSNs are effectively 
tuned by varying several key processing conditions such as polymer block length, 
solvent type and reactant concentrations. This enables us to elicit a synergistic 
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combination of merits derived from both hollow silica nanocapsules and Pluronic® 
micelles. Fluorescent PEOSNs are then prepared by sequestering the fluorescent 
conjugated polymer MEH-PPV into the core of Pluronic® micelles, followed by 
subsequent interfacial silica condensation. Moreover, their application as effective 
fluorescent probes for bioimaging is conclusively demonstrated by using the 
transgenic zebrafish line TG(fli1:EGFP), wherein the zebrafish Fli1 promoter is used 
to drive the expression of enhanced green fluorescent protein (EGFP) in the vessels 
and highlight all vascularized tissues with green fluorescence.[28,29] This provides a 
strong contrast against the red fluorescent PEOSNs in the confocal images. Besides, 
the zebrafish development is relatively fast and stereotypical such that most organs are 
vascularized and functional by 5 days of post fertilization.[29] The manipulated larvae 
can also be mounted alive in low melting agarose and are small enough for non-
invasive, whole animal imaging. Therefore, TG(fli1:EGFP) is an excellent vertebrate 
model to ascertain the biocompatibility and in vivo behavior of the fluorescent 
PEOSNs. 
 
3.2 Experimental Details 
3.2.1 Materials 
 
Tri-block copolymer Pluronic® L121 (PEO5PPO70PEO5), P123 (PEO20PPO70PEO20), 
F127 (PEO106PPO70PEO106), tetramethylorthosilicate (TMOS; 98%), tetrahydrofuran 
(THF), dimethylformamide (DMF) and poly(2-methoxy-5-(2-ethyl-hexyloxy)-1,4-
phenylenevinylene) (MEH-PPV) were obtained from Sigma Aldrich and used without 
further purification. 
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3.2.2 Synthesis of PEOSNs 
 
PEOSNs were prepared using a procedure reported previously.[27] In a typical 
synthesis, a polymer solution of the desired concentration was prepared by dissolving 
the respective polymers (Pluronic® L121, P123 or F127) into 900 μL of THF. To each 
of these polymer solutions, 65 μL of TMOS was then added. The mixed solution was 
injected into 10 g of deionized water immersed in a water-bath under ultra sonication 
in 3 minutes. The solution was sonicated for 10 more minutes, followed by stirring at 
room temperature for four days to evaporate off THF and ensure a complete 
hydrolysis and condensation of TMOS at the interface between the core and corona of 
the copolymer micelles. The amount of block copolymers and TMOS used were 
subsequently varied systematically to study their influence on the formation of 
PEOSNs. Mixtures of THF and DMF in various ratios are also used to investigate 
their effect on the core-shell morphology (where the total volume of solvents used 
before injecting into water is kept at 900 μL for all experiments). 
 
3.2.3 Synthesis of fluorescent PEOSNs 
 
Fluorescent conjugated polymer MEH-PPV was first dissolved in THF to form a stock 
solution of 1.0 mg/mL. 75 μL of this stock solution was then mixed with 75 mg of 
F127 dissolved in 825 μL of THF. Next, 65 μL of TMOS was added and the resultant 
mixture solution was subsequently injected into 10 g of deionized water while being 
sonicated in a water bath for 3 minutes. The solution was sonicated for another 10 
minutes, followed by stirring at room temperature for four days. 
 




TEM (JEM-2010F, 200 kV) was employed to study the morphology of the as-
synthesized PEOSNs. To prepare the sample for TEM analysis, 40 μL of an aqueous 
suspension of PEOSNs was diluted with 200 μL of deionized water. A small drop of 
this diluted solution was pipetted directly onto a 200-mesh carbon-coated copper grid. 
After 2 minutes, the excess solution was removed by touching the grid edge using a 
Kimwipe delicate wipe. The sample was finally dried at room temperature in 
preparation for TEM analysis. Dynamic light scattering (DLS) was performed with 
Malvern Zetasizer Nano-S using a HeNe laser (633 nm) to measure the nanocapsule 
size and size distribution. The spectrometer was calibrated by using a standard 
polystyrene suspension of 60 nm. All measurements were conducted using water as 
the dispersant in a glass cuvette. 29Si NMR characterization was conducted using a 
Bruker Avance 400 (DRX400) NMR spectrometer at 400 MHz at room temperature. 
The sample was loaded into 4.0 mm Zirconia PENCILTM rotors and capped tightly. 
The 29Si spectrum was recorded at 79.489 MHz with a repetition delay of 10 s. A 35-
ms acquisition time, spin rate of 10,000 rps and 3000 number of scans were 
employed. Chemical shifts of 29Si NMR were referenced to tetramethylsilane as 0 
ppm. 
 
3.2.5 Zebrafish care and confocal fluorescence imaging 
 
The transgenic zebrafish line, TG(fli1:EGFP), is used as the vertebrate model for the 
microinjection of fluorescent PEOSNs. This transgenic line expresses the green 
fluorescent protein in the heart and all blood vessels of the embryo.[28] TG(fli1:EGFP) 
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was maintained in the Institute of Molecular and Cell Biology (IMCB) zebrafish 
facility. The embryos were obtained and experiments were conducted in accordance to 
IACUC rules (the Biopolis IACUC application #090430) and established methods.[30] 
To prevent the formation of melanin and ensure optical translucence of transgenic 
larvae for confocal imaging, 1-phenyl-2-thiourea was added to zebrafish embryos at 
22 hours post fertilization. For the introduction of silica nanocapsules into the 
zebrafish circulation, 3 days old TG(fli1:EGFP) larvae were mounted ventral side up 
in 1% UltraPure™ low melting point agarose (Invitrogen) and fluorescent PEOSNs 
were microinjected into the sinus venosus. For monitoring of localized uptake of silica 
nanocapsules, 3 days old TG(fli1:EGFP) larvae were mounted dorsal side up in 1% 
UltraPure™ low melting point agarose and fluorescent PEOSNs were microinjected 
into the brain ventricle. Confocal microscopy images were acquired with an upright 
(Zeiss Axiovert200M) laser scanning microscope (LSM Meta 510, Carl Zeiss) using 
two laser lines (30 mW Argon and 1 mW HeNe) as the excitation source and 
visualized using the 505/530 nm and 560/615 nm emission band-pass filters 
respectively. Images were acquired under the same setting for all microinjected larvae. 
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3.3 Results and discussion
3.3.1 Synthesis and optimization of PEOSNs 
 
Scheme 3.1 The formation mechanism of PEOSNs. 
As illustrated in Scheme 3.1, our strategy of preparing PEOSNs lies in the 
sequestration of TMOS to the hydrophobic micellar core during the self-assembly of 
Pluronic® block copolymers micelles. Subsequent contact with water molecules at the 
core-corona interface results in the hydrolysis and condensation of TMOS to form a 
thin silica shell. In this regard, the condensation reaction frontline is on the outer 
circumference of the interfacial shell. Hydrolyzed TMOS will then diffuse through the 
silica layer and condense on the outer shell surface. Hence, upon initiation at the core-
corona interface, the silica shell will extend radially outwards into the hydrophilic 
PEO corona as the reaction time progresses. 
In addition, the silica shell should ideally be sufficiently thin so that the PEO corona 
will not be completely enveloped by a thick silica layer at the interfacial region. 
Instead, free PEO chains can extend from the surface to function as steric stabilizers 
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and prevent the silica nanocapsules from agglomeration. The PEO chains will also 
offer the opportunity to conjugate other functional groups, such as FA, for targeted 
diagnosis and delivery of payloads.[31] Meanwhile, a minimum thickness of the silica 
shell must still be maintained so as to enhance the mechanical integrity of the 
Pluronic® micelles and ensure that they remain stable even when subjected to high 
dilution conditions in physiological environments. Therefore, PEOSNs exhibit a 
synergistic improvement in biomechanical properties to a level which cannot be 
achieved if the silica nanocapsules and Pluronic® micelles are applied separately. 
 
Development of such a robust and colloidally stable nanocarrier is facilely achieved 
by our interfacial templating scheme, wherein various synthesis parameters can be 
varied to control the size and core-shell morphology of PEOSNs for the development 
of an optimized nanocapsule structure. To investigate the effect of PEO block length 
on the formation of the resultant silica nanocapsules, the triblock copolymers L121 
(PEO5PPO70PEO5), P123 (PEO20PPO70PEO20) and F127 (PEO106PPO70PEO106) are 
selected as templating agents because there is a significant variation in the PEO block 
length while the PPO block length remains the same. For comparison purpose, the 
physicochemical properties of these block copolymers are listed in Table 3.1.[32] 
 
Table 3.1 Physicochemical properties of Pluronic® block copolymers 
Chemical Formula Trade name Molecular weight PEO wt% Cloud pointa/°C HLBb 
PEO5PPO70PEO5 L121 4400 10 14 1-7 
PEO20PPO70PEO20 P123 5750 30 90 7-12 
PEO106PPO70PEO106 F127 12600 70 >100 22 
 
a Cloud point is determined for 1% aqueous solution and indicates the temperature at which the 
copolymer solution starts to separate. b HLB measures the degree to which the amphiphilic 
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Employing L121 as a templating agent results in the formation of silica aggregates 
without a typical core-shell morphology (Figure 3.1a). The inability of L121 to self-
assemble into polymeric micelles for the templated formation of silica nanocapsules is 
evidenced by DLS analysis too, which indicates the largest hydrodynamic diameter of 
650 nm for silica particles arising from L121 as the template (Figure 3.1d). This 
suggests the presence of extensive particle aggregation. Macroscopically, precipitation 
is observed and this confirms the colloidal instability of L121 mixture solution. These 
findings could be attributed to the short PEO block length of L121, which limits the 
aqueous solubility of the block copolymers and its tendency to form micelles. Such 
characteristics are also supported by the low hydrophilic-lipophilic balance (HLB) and 
cloud point of L121, as listed in Table 3.1. As a result, no silica nanocapsules are 
formed when L121 is selected as the templating agent. 
 
Figure 3.1 TEM images of the PEOSNs derived from: (a) L121, (b) P123, (c) F127 block copolymers, 
and (d) their corresponding DLS results. For each synthesis, 75 mg of the polymer and 65 μL of TMOS 
are used. 
Chapter 3: Surface-Decorated Silica Nanocapsules  
 56 
In comparison, P123 and F127 block copolymers have larger HLB values and higher 
cloud points. Thus, they form micelles readily at room temperature to direct the 
formation of PEOSNs, as indicated by the distinct core-shell morphology of PEOSNs 
derived from P123 and F127 as templates (Figure 3.1b and 3.1c). Nevertheless, while 
agglomeration is observed with the P123-templated PEOSNs (Figure 3.1b), the F127-
templated PEOSNs have a relatively uniform dispersion in aqueous solution (Figure 
3.1c). DLS analysis also indicates that F127-templated PEOSNs exhibit the smallest 
hydrodynamic diameter of 25 nm (Figure 3.1d). 
 
From these observations, it highlights the importance of sufficiently long PEO block 
segments to overcome the susceptibility of the PEOSNs towards agglomeration. With 
progressing time, growth of the silica shell will proceed radially outwards from the 
core-corona interface. Hence, due to the gradual encroachment of silica network into 
the hydrophilic PEO corona, the shorter PEO chains of P123 are unable to provide 
effective steric stabilization to keep the silica nanocapsules from agglomerating 
together. As such, F127 is determined to be the preferred choice for templating agent 
in the synthesis of colloidally stable PEOSNs due to its favourable block copolymer 
composition. 
 
F127 block copolymer is known to undergo a sol-gel phase transition at sufficiently 
high concentration,[32,33] during which the F127 micelles are closely packed together 
and the system becomes highly viscous. Thus, low F127 concentration regimes of < 
1.5 wt% were maintained for all synthesis conditions in order to ensure the formation 
of well-separated F127 micelles.[32] The morphological evolution of PEOSNs with 
varying amount of F127 from 25 to 125 mg (i.e. 0.25 to 1.25 wt%) is then investigated 
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by TEM (Figure 3.2) and DLS (Figure 3.3). Herein, the core size of PEOSNs refers to 
the inner diameter of the silica shell whereas the outer diameter of PEOSNs includes 
the contribution from the silica shell thickness. 
 
Figure 3.2 TEM images of PEOSNs synthesized at various amount of F127 block copolymers: (a) 25 
mg, (b) 50 mg, (c) 75 mg, (d) 100 mg, and (e) 125 mg. For each synthesis, 65 μL of TMOS is used. 
 
 
Figure 3.3 DLS results of the PEOSNs prepared at various amount of F127 block copolymers. For each 
synthesis, 65 μL of TMOS is used. 
 
At a fixed TMOS concentration, a decreasing amount of F127 used causes more 
TMOS molecules to be partitioned within each micellar core. Hence, F127 polymeric 
micelles are expected to undergo a higher degree of core swelling, and this accounts 
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for the increase in average core size and outer diameter of PEOSNs from 4.8 to 8.0 
nm and 12.7 to 17.8 nm respectively, when the amount of F127 used is reduced from 
125 to 25 mg (Figure 3.4a). In addition, when the ratio of F127 to TMOS decreases, 
more silica is expected to condense in the PEO corona region and this reduces the 
effective length of the free PEO chains projecting from the nanocapsule surface. 
Therefore, agglomeration is more likely to take place, as suggested from the marked 
increase in hydrodynamic diameter of PEOSNs at lower amount of F127 (25 - 50 mg) 
shown in Figure 3.3. 
 
Figure 3.4 The average outer and core diameters of PEOSNs synthesized at varying amount of: (a) 
F127, and (b) TMOS, as measured from TEM. 
 
Conversely, at a fixed F127 concentration, increasing the amount of TMOS used from 
25 to 125 μL brings about an enlargement of the average core size and outer diameter 
of PEOSNs from 5.5 to 7.0 nm and 12.8 to 16.5 nm respectively (Figure 3.4b). 
Formation of a thicker silica shell at higher TMOS concentrations also results in a 
more well-defined core-shell morphology (Figure 3.5). As such, a balance must be 
struck since a high F127 to TMOS ratio will hamper the formation of a well-defined 
core-shell morphology while a low F127 to TMOS ratio can cause a greater 
susceptibility towards particle agglomeration. This is indicated by the gradual cross-
linking between PEOSNs to form “pearl-necklace” aggregates (Figure 3.5e) and a 
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considerable increase in the hydrodynamic diameter of PEOSNs when 125 μL of 
TMOS is used (Figure 3.6). 
 
Figure 3.5 TEM images of PEOSNs synthesized at various amount of TMOS: (a) 25 μL, (b) 50 μL, (c) 
75 μL, (d) 100 μL, and (e) 125 μL. For each synthesis, 75 mg of F127 is used. 
 
 
Figure 3.6 DLS results of the PEOSNs prepared at various amount of TMOS. For each synthesis, 75 mg 
of F127 is used. 
 
Despite the variations in synthesis conditions, the hydrodynamic diameter of PEOSNs 
is consistently larger than its corresponding outer diameter as determined from TEM 
analysis. This can be ascribed to the PEO chains extending from the outer surface of 
the silica shell, which exhibit no contrast in the TEM images due to their low electron 
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densities,[27] but are reflected in the DLS size measurement. This also confirms the 
interfacial templating nature of our method whereby the silica shell is formed between 
the PPO core and PEO corona of the F127 micelles. Next, in order to elucidate the 
influence of solvent type on PEOSNs formation, the size and morphology of PEOSNs 
synthesized in a mixture of THF and DMF at various mixed solvent ratio of THF/ 
DMF are investigated by TEM (Figure 3.7). 
 
Figure 3.7 TEM images of PEOSNs synthesized at different mixed solvent ratio (THF/DMF): (a) 1/0, 
(b) 3/1, (c) 1/1, (d) 1/3, and (e) 0/1. For each synthesis, 75 mg of F127 and 65 μL of TMOS are used. 
 
As shown in Figure 3.8, when the volume fraction of DMF increases, both the core 
size and outer diameter of the F127-templated PEOSNs increases. This is attributed to 
the slower evaporation rate of DMF (boiling point of 155 °C) than that of THF 
(boiling point of 65 °C). As a result, at larger volume fractions of DMF, the higher 
content of DMF retained in the micellar core leads to core swelling and the 
subsequent formation of an enlarged silica shell. Besides, the addition of DMF to 
enhance the silicate condensation degree of PEOSNs is also demonstrated by 29Si 
NMR spectroscopy. In the 29Si NMR spectra of Figure 3.9a, the three peaks at 
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approximately –92, –102 and –112 ppm can be assigned to the Q2, Q3 and Q4 species, 
respectively. Since Q4 species denotes a greatest extent of silicate polymerisation, the 
condensation degree of PEOSNs can thus be estimated by determining the area ratio 
of Q4/(Q2+Q3). As such, our study suggests the formation of a more condensed silica 
shell at higher volume fractions of DMF, as illustrated in Figure 3.9b. This has 
positive implications for drug delivery and controlled release applications, because the 
permeability of the silica shell can then be effectively tuned by varying the amount of 
DMF used. 
 
Figure 3.8 The average outer and core diameters of PEOSNs synthesized at different mixed solvent 
ratio (THF/DMF), as measured from TEM. 
 
 
Figure 3.9 (a) 29Si NMR spectra of PEOSNs synthesized at different mixed solvent ratio (THF/DMF), 
and (b) the corresponding condensation degree of PEOSNs, as determined by the area ratio of 
Q4/(Q2+Q3). 
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3.3.2 In vivo imaging of fluorescent PEOSNs in zebrafish 
 
In order to demonstrate the application of PEOSNs as effective nanocarriers for 
bioimaging, fluorescent PEOSNs are prepared by encapsulating conjugated polymer 
MEH-PPV, which emits red fluorescence, into the interior of silica nanocapsules. The 
transgenic zebrafish line TG(fli1:EGFP) is then selected as the vertebrate model for in 
vivo study with standard laser scanning microscopic technique. After injecting the 
fluorescent PEOSNs into the developing zebrafish larvae, the latter is re-iteratively 
imaged over many days to assess the biocompatibility, track spatial temporal 
biodistribution and evaluate the biostability of the injected fluorescent probes. 
 
Biocompatibility is assessed by the impact of the fluorescent PEOSNs on organ/larvae 
growth, as well as the gain in vascular network complexity of the zebrafish larvae at 
different time point of post-injection. Confocal imaging immediately after injection 
into the cardiac cavity shows that the fluorescent PEOSNs are well dispersed in vivo 
because both pericardium (the viscous fluid around the heart) and the internal content 
of the heart fluoresce a uniform red (Figure 3.10a). Importantly, the injected larvae 
remain viable because the heart continues to grow in size and complexity even after 3 
days post-exposure to fluorescent PEOSNs (Figure 3.10b). This confirms the 
biocompatibility of PEOSNs as a synthetic dye carrier. 
 
Cellular uptake of fluorescent PEOSNs is also demonstrated by the emergence of red 
fluorescent cells in the cardiac cavity (Figure 3.10b). To further assess the extent of 
cellular uptake by various cells in the zebrafish larvae, the biodistribution of 
fluorescent PEOSNs is examined in the whole larvae, 1-day post injection (Figure 
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3.11). It is observed that red fluorescent cells are predominantly detected close to the 
green fluorescent (GFP-positive) vessels. Figure 3.11(d-f) illustrate some vessels that 
are imaged at higher magnifications. 
 
Figure 3.10 (a) Confocal images of zebrafish heart immediately after injection of fluorescent PEOSNs; 
and (b) the same injected larvae imaged 3 days later. (This work is done in collaboration with IMCB.) 
 
Figure 3.11 Confocal images of transgenic zebrafish larvae illustrating the biodistribution and uptake 
of fluorescent PEOSNs after 1 day post injection into the heart. Selected areas are enlarged in (d), (e) 
and (f). (This work is done in collaboration with IMCB.) 
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The biostability of fluorescent PEOSNs is assessed by investigating the extent to 
which the red fluorescent signal could be retained after cellular internalization of the 
silica nanocapsules. This is achieved by direct microinjection of the fluorescent 
PEOSNs into the brain ventricle. It is important to note that this procedure is 
relatively benign when performed on young zebrafish larvae and allows one to 
address the extent of cellular uptake after localized delivery of fluorescent PEOSNs.  
 
 For Figure 3.12a, the brain ventricle when imaged immediately after microinjection, 
is highlighted by red fluorescence which is contributed by the injected fluorescent 
PEOSNs. Confocal imaging of the same injected larva, 7 days later, still indicates the 
presence of red fluorescent-labelled cells that are predominantly lining around the site 
of injection (Figure 3.12b). This illustrates the biostability of fluorescent PEOSNs. 
More interestingly, the in vivo biocompatibility of fluorescent PEOSNs is strongly 
supported by the continued brain vascularization in the same injected larva by 
comparing the vascular network in Figure 3.12a with that of 7 days later in Figure 
3.12b. Therefore, the studies conducted in zebrafish in our present work strongly 
support the use of fluorescent PEOSNs as a biocompatible and effective tool for 
labelling cells in vivo. 
 
Figure 3.12 (a) Confocal images of transgenic zebrafish larvae illustrating the cellular uptake and 
biostability of fluorescent PEOSNs immediately; and (b) 7 days post injection into the brain ventricle. 
(This work is done in collaboration with IMCB.)  




We have successfully developed a class of robust silica-based nanocapsules via a 
novel interfacial hydrolysis and condensation scheme, confined at the interface 
between the PPO core and PEO corona of self-assembled F127 polymeric micelles. 
The silica nanocapsules are surface-decorated with a layer of PEO chains and thus are 
stable in aqueous and physiological environments. Our study demonstrates the precise 
tuning of the structure and morphology of PEOSNs by manipulating several synthesis 
parameters such as the PEO block length, concentration of block copolymers and 
TMOS, as well as the type and ratio of mixed solvents. 
 
To demonstrate the application of PEOSNs for bioimaging, we uploaded fluorescent 
conjugated polymer MEH-PPV into the interior of PEOSNs and conducted in vivo 
studies with the transgenic zebrafish line TG(fli1:EGFP). The biocompatibility is 
demonstrated by cellular internalization of these fluorescent PEOSNs, which do not 
interfere with larval development nor affect vessel growth, while the biostability of 
fluorescent PEOSNs is further supported by the presence of fluorescent-labelled cells 
7 days post-exposure to the microinjected silica nanocarriers. 
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Chapter 4  





Over the past two decades, considerable efforts have been made with the development 
of 3d transition metal oxide nanoparticles owing to their enormous potential for 
applications in various fields including bioimaging. In particular, MONs have been 
investigated not only for fundamental scientific interest, but also for many 
technological applications such as MRI. On the atomic scale, MnO has a cubic NaCl 
rock salt structure, where the magnetic moments of Mn atoms are aligned within the 
(111) planes to form ferromagnetic (111)-type sheets that stack antiferromagnetically 
along the (111) axis.[1] Hence, MnO is antiferromagnetic with a Néel temperature of 
118K. Above the Néel temperature, the material exerts paramagnetism and can be 
used to enhance the proton relaxation of surrounding water molecules under the 
influence of an external magnetic field.[2] 
 
Nonetheless, for the application of MONs as MRI contrast agents, it is important for 
the nanoparticles to be of a narrow size distribution because the properties of 
nanoparticles are directly dependent on their sizes and surface-to-volume ratio. 
Therefore, a tremendous amount of research has been performed to develop a 
synthesis protocol for uniformly sized MONs with controlled sizes.[3,4] In recent years, 
numerous techniques have been proposed to produce monodisperse MONs. For most 
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of these methods reported, they typically involve thermal decomposition of a suitable 
precursor (e.g. manganese acetylacetonate[5], acetate[6] or formate[7]) in a non-polar 
solvent at high temperatures. However, as the as-synthesized nanoparticles exhibit a 
high surface energy state and thus are susceptible to aggregation, oleic acid is usually 
added during the synthesis procedure to stabilise the nanoparticles in their 
thermodynamically unfavourable state. Consequently, one expects that there is an in 
situ generation of the manganese oleate complex during the reaction.[3] 
 
Herein, in the present study, we report on the use of manganese oleate complex as the 
precursor for the size-controlled synthesis of MONs. Nonetheless, as the precursor is 
not readily available for purchase, we have opted to synthesize the precursor from 
inexpensive starting materials. Moreover, the influence of various synthesis 
parameters on the size and size distribution of MONs is investigated systematically by 
varying the type of solvent, reaction time and reaction temperature. 
 
4.2 Experimental Details 
4.2.1 Materials 
 
Manganese (II) chloride tetrahydrate (MnCl2.4H2O), oleic acid, methanol, anhydrous 
sodium hydroxide (NaOH) pellets, anhydrous magnesium (II) sulphate (MgSO4), 
ethanol, acetone, hexane, THF, 1-octadecene, 1-hexadecene, 1-tetradecene and 
trioctylphosphine oxide (TOPO, 90% technical grade) were used as received without 
any further purification. 
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4.2.2 Synthesis of manganese oleate precursor 
 
Manganese oleate was prepared according to a previously published report[3], but with 
some modifications. For a typical reaction, 7.94 g of MnCl2.4H2O and 22.60 g of oleic 
acid were dissolved in 200 mL of methanol to form a clear, colourless solution. Next, 
3.2 g of anhydrous NaOH pellets was dissolved in another 200 mL of methanol. The 
solution was stirred continuously for 1 hour at 50°C and the residual undissolved 
NaOH particles were then filtered off. This was followed by a drop wise addition of 
NaOH/methanol solution to the Mn2+/oleic acid/methanol solution under stirring over 
a period of 1 hour. During the process, the solution was observed to turn from 
colourless to pink and a deep red oily substance was precipitated. This mixture was 
then left to stir for an additional 1 hour. After stirring, the solvent was discarded and 
the product was washed in the following order: four times with water, once with 
ethanol, and once with acetone. Next, the oily residue was dissolved in hexane solvent 
to produce a deep red solution. Traces of water present from the previous washing 
step were removed from the solution through centrifugation, followed by the addition 
of 5 g anhydrous MgSO4 powder. The mixture was left to dry overnight, after which, 
the MgSO4 powder was filtered from the solution. Finally, the hexane solvent was 
evaporated to yield a deep red waxy solid. The resultant product was then dried in a 
vacuum oven at 125°C for 2 hours to yield the manganese oleate precursor. 
 
4.2.3 Synthesis of monodisperse MONs 
 
For a typical reaction, 1.24 g of the manganese oleate complex synthesized as 
described above was dissolved in 10 g of 1-octadecene to produce a deep, red 
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solution. The solution was degassed at 70°C for 2 hours under a vacuum to remove 
the moisture and oxygen. The reaction flask was then backfilled with argon. Next, the 
solution was initially heated to 200°C at approximately 10°C/min with vigorous 
stirring. For the next heating step, the solution was further heated to 300°C at a fixed 
heating rate of 3°C/min. During this process, it was observed that the solution turned 
gradually from deep red to light brown. At higher reaction temperatures, a pale green 
precipitate was produced, resulting in the formation of an olive green mixture. This 
indicated that manganese oleate had been thermally decomposed to form MONs. 
Finally, the mixture solution was maintained at 300°C for an additional hour, before 
being cooled to room temperature. 
 
To wash the synthesized MONs, 80 mL of ethanol was added to the cooled reaction 
mixture. The precipitated nanoparticles were subsequently isolated by centrifugation 
at 6000 rpm, before being re-suspended in 15 mL of THF. This washing step 
(precipitation, centrifugation and redispersion) was repeated for two more cycles and 
the purified MONs were finally re-suspended in THF to make a stock solution at a 
concentration of 20 mg/mL. To obtain MONs of different sizes, the aforementioned 
procedure was altered by changing the type of solvent (1-octadecene/1-hexadecene/1-
tetradecene), reaction temperature and reaction time. 
 
4.2.4 Synthesis of hollow MONs 
 
Hollow MONs were prepared according to a previously reported method.[8] Briefly, 10 
mL of the MON stock solution was added to 10 g of TOPO under vigorous stirring. 
The solution was degassed under vacuum for 1 hour, then heated up to 300°C in an 
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inert argon atmosphere. The solution was maintained at 300°C for 2 hours before 
cooling down to room temperature. The nanoparticles were precipitated with 30 mL of 




TEM (JEM-2010F, 200 kV) was employed to study the size and morphology of 
MONs. X-ray diffraction (XRD, Bruker AXS D8 Advance) was conducted to identify 
the crystalline phase of MONs. Phase analyses were carried out under Cu Kα 
radiation (λ = 1.5406 Å) at a scanning rate of 2θ = 2 °/min over a range of 2θ = 30 - 
90°. Fourier transform infrared spectroscopy (FT-IR, Varian 3100 Excalibur) was 
employed to determine the chemical composition of oleic acid, manganese oleate and 
as-synthesized MONs. Thermogravimetric Analysis (TGA) was performed by using 
TGA Q500 Thermal Instrument with a heating rate of 10°C/min to 700°C in air 
ambient. 
 
4.3 Results and discussion 
4.3.1 Synthesis of manganese oleate precursor 
 
Since the monodisperse MONs are formed by thermal decomposition of the precursor 
in a suitable solvent, TGA is performed to monitor the decomposition behaviour of 
manganese oleate. Figure 4.1a shows the TGA curve of the as-prepared manganese 
oleate. The experiment is conducted in a nitrogen atmosphere at a heating rate of 
10°C/min. The decomposition of manganese oleate is initiated between 240°C to 
250°C. This is followed by a sharp mass loss from 250°C to 420°C. The 
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decomposition rate is at a maximum over the temperature region of 250°C to 310°C 
while the mass of the remaining solid residue is 11.6% of the starting material. 
Assuming that the remaining material after thermal decomposition is MnO (molar 
mass of 70.94 g/mol), the starting material will have a molar mass of 611.6 g/mol. 
This is in a good agreement to the theoretical molar mass of manganese oleate (616.94 
g/mol). Besides, reports in available literature have described manganese oleate as a 
waxy, dark red solid.[9] Since this corresponds to the physical appearance of our 
synthesized precursor, it suggests that the precursor is likely to be the desired 
manganese oleate compound. 
 
Figure 4.1 TGA curves of: (a) manganese oleate precursor; and (b) as-synthesized MONs. 
 
FT-IR is also performed to characterize the phase purity of oleic acid, manganese 
oleate precursor and the as-synthesized MONs (Figure 4.2). It is noteworthy that for 
oleic acid and manganese oleate, both spectra show the four characteristic bands of 
the oleyl group –OOC–(CH2)7–CH=CH-(CH2)7-CH3. The weak absorption band at 
3006 cm-1 is attributed to the asymmetric stretching of the vinyl C-H bond while the 
band at 2954 cm-1 is indicative of the asymmetric CH3 stretching mode. The 
symmetric and asymmetric stretching of the CH2 bond can be assigned to the bands at 
2925 cm-1 and 2854 cm-1. Yet, there is one distinct difference between the two spectra. 
For oleic acid, due to the presence of the –COOH group, there is a strong absorption 
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band at 1711 cm-1. However, this is absent in the spectrum of the precursor; instead, 
there are two bands at 1553 cm-1 and 1430 cm-1 which are representative of the 
RCOO- group.[3] Therefore, this serves to confirm the identity of the precursor as 
manganese oleate. 
 
Figure 4.2 FT-IR spectra of oleic acid, manganese oleate and the as-synthesized MONs. 
 
4.3.2 Synthesis and characterization of monodisperse MONs 
 
In a typical reaction to synthesize monodisperse, hydrophobic MONs, the pre-formed 
manganese oleate complex is first dissolved in 1-octadecene solvent. The solution is 
heated to 300˚C and kept at that temperature for 1 hour. The TEM image and the 
corresponding particle size distribution of the resulting MONs formed under these 
standard conditions are shown in Figure 4.3. The average diameter of the particles is 
calculated to be 16.0 nm, with a standard deviation σ = 8.6%. Thus, this suggests that 
through this synthesis route, fairly monodisperse MONs could be successfully formed. 
Having such a narrow size distribution is essential as the properties of nanoparticles 
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are strongly dependent on their dimensions. In addition, from Figure 4.3, high 
resolution TEM is performed on one of the MONs and the highly crystalline nature of 
the nanocrystal is evidenced by the presence of a distinct lattice fringe pattern. 
Calculations suggest that the inter-planar spacing for this nanoparticle is about 2.54 
angstroms, thus it corresponds closely to the theoretical (111) plane of MnO (2.5651 
Å). 
 
Figure 4.3 TEM images of MONs at different magnifications and the corresponding particle size 
distributions, based on the statistical assembly of 100 nanoparticles. 
 
XRD phase analysis is also conducted in order to investigate the phase purity and 
crystal structure of the MONs. For these 16 nm-sized MONs, the characteristic 
diffraction peaks of manganosite (MnO) are evident in the sample. Based on the 
JCPDS 89-4835 (JCPDS = Joint Committee on Powder Diffraction Standards), these 
diffraction peaks can be assigned to the (111), (200), (220), (311), (222) and (400) 
planes, as indicated in Figure 4.4a. This is further verified by the SAED pattern as the 
diffraction rings are consistent with the MnO phase (Figure 4.4b). Moreover, by 
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fitting a Gaussian distribution to the (200) diffraction peak (inset), the full width at 
half maximum (FWHM) is subsequently obtained and used to calculate the average 
crystallite size d, based on the Scherrer equation. 
 
Figure 4.4 (a) XRD trace of MONs. The average crystallite size of MONs (d = 14.4nm) is calculated 
using the Debye-Scherrer formula. (b) SAED pattern of MONs. 
 
It is estimated that the as-synthesized MONs exhibit an average crystallite size of 14.4 
nm. When compared to the average particle size as measured by TEM image (Figure 
4.3), there is good agreement between the two values obtained. The small discrepancy 
in size measurement can be attributed to the fact that nanoparticles tend to exhibit a 
solid core surrounded by a liquid/amorphous surface shell.[10,11] Since this thin 
liquid/amorphous film layer will not be taken into account in the Scherrer equation, 
the average crystallite size calculated from the XRD spectrum should be slightly 
smaller than the particle size measured from the TEM image. Alternatively, it may 
also be due to the limited statistical assembly for TEM (~100 particles). As a result, a 
greater uncertainty is introduced in the determination of the average particle size.[1] 
 
Due to the small particle sizes, MONs exhibit a high level of surface energy and are 
thermodynamically unstable. As such, surface ligands have to be present in order to 
stabilize the nanoparticles against aggregation. In this case, the oleate group plays the 
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role of a capping agent by binding to the surface of MONs. The presence of such an 
organic coating is evidenced from the TGA curve in Figure 4.1b, which illustrates 
similar decomposition behaviour to manganese oleate (Figure 4.1a). This suggests that 
the organic coating is largely constituted of the oleate group. From Figure 4.1b, it is 
estimated that the amount of oleate on the nanoparticle surface is approximately 8.8% 
of the total mass. 
 
4.3.3 Size Variation of MONs 
 
Once the facile synthesis strategy in the present work is shown to be capable of 
producing MONs of a narrow size distribution, various synthesis parameters are 
adjusted in order to control the particle size and size distribution. Being able to fine-
tune the particle size is important because the contrast enhancement of the MR signal 
is strongly dependent on the size of the contrast agent used.[3] 
 
4.3.3.1 Influence of reaction temperature 
 
The evolution of particle size with reaction temperature is studied: Manganese oleate 
precursor, dissolved in 1-octadecene solvent, is heated to different temperatures (i.e. 
260°C, 280°C, 300°C and 318°C). All the reaction mixtures are then aged for 1 hour 
at their respective temperatures. As can be observed from the insets of Figure 4.5, 
when the reaction mixture is separately heated to 260°C, 280°C, 300°C and 318°C, 
the nanoparticles grew to a mean diameter of 14.3 ± 1.8 nm, 15.1 ± 1.0 nm, 16.0 ± 1.4 
nm and 22.1 ± 1.7 nm respectively. Therefore, there is a positive correlation between 
reaction temperature and nanoparticle size, which can be attributed to the dependence 
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of particle growth kinetics on temperature. However, the effectiveness of reducing the 
nanoparticle size further by varying the reaction temperature is limited because the 
minimum reaction temperature must be greater than 250C. This is the temperature to 
initiate the decomposition of manganese oleate, as indicated in Figure 4.1a. 
 
Figure 4.5 TEM images of MONs synthesized at different reaction temperatures: (a) 260°C, (b) 280°C, 
(c) 300°C, (d) 318°C. Insets are the corresponding particle size distributions. 
 
4.3.3.2 Influence of solvent 
 
The nanoparticle size can also be controlled by varying the type of solvent used. As 
shown in Figure 4.6, smaller MONs size could be achieved when shorter carbon-chain 
hydrocarbons are used instead of 1-octadecene. Herein, the nanoparticles grew to a 
mean diameter of 13.4 ± 1.0 nm (Figure 4.6a) and 15.2 ± 1.0 nm (Figure 4.6b) when 
synthesized in 1-hexadecene solvent at 260°C and 275°C respectively. Meanwhile, 
when the reaction was carried out in 1-tetradecene solvent at 250°C, MONs of 8.2 ± 
1.1 nm in sizes were produced (Figure 4.6c-e). Therefore, our results suggest that 
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smaller MONs are readily yielded when the hydrocarbon chain length of the alkene 
solvent is reduced. This could be ascribed to a higher degree of solvent stabilization 
provided by the shorter chain alkene, thereby increasing the thermal stability of the 
Mn-oleate complex. Hence, in accordance with the LaMer model, its decomposition 
kinetics would occur at a higher temperature and lead to the formation of a large 
amount of MnO nuclei but of smaller radii.[13] 
 
Figure 4.6 TEM images of MONs synthesized in 1-hexadecene solvent: (a) 260°C (b) 275°C. Insets are 
the corresponding particle size distribution. TEM images of MONs synthesized in 1-tetradecene solvent 
at 250°C: (c) low and (d) high magnification with (e) the corresponding particle size distribution. 
 
Nonetheless, the choice of hydrocarbon solvents is restricted by their boiling points. It 
is well-established that the boiling point of hydrocarbons would decline drastically 
with decreasing carbon-chain length. Therefore, it is challenging to synthesize sub-5 
nm MONs by adjusting the solvent type alone, especially if the maximum temperature 
as capped by the boiling points of non-polar solvents is below the temperature 
required to initiate the thermal decomposition of manganese oleate precursor. 
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4.3.3.3 Influence of reaction time 
 
There is a positive correspondence between the average particle size and reaction time 
too. When the reaction is allowed to age separately for 10, 30, 60, 120 and 180 min, 
the nanoparticles demonstrated an average diameter of 7.7 ± 2.0, 9.8 ± 2.1, 16.0 ± 1.4, 
26.6 ± 2.4 and 32.3 ± 5.6 nm respectively (Figure 4.7). Therefore, it is observed that 
while the variation of reaction time would enable a wide range of particle size to be 
attained, the particle size distribution is also affected. In fact, it is observed that the 
MONs had the narrowest size distribution at an optimal reaction time of 60 min. 
 
Figure 4.7 TEM images of MONs after: (a) 10, (b) 30, (c) 60, (d) 120, and (e) 180 min. (f) Evolution of 
particle size (bottom) and size distribution (top) with reaction time. 
 
The influence of reaction time on the particle size can be explained by the 
“focusing/defocusing of size distribution” concept.[14] Briefly, this theory postulates 
that at sufficiently high monomer concentrations, the smaller nanocrystals tend to 
grow faster than the larger ones. Thus, there is a “focusing” of the size distribution to 
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yield highly monodisperse nanoparticles. However once the monomer concentration is 
depleted, the size distribution “defocuses” and broadens as a result of the Ostwald 
ripening, during which, the larger nanocrystals continue to grow while the smaller 
ones shrink and disappear eventually. 
 
In this case, when the reaction mixture is heated to 300°C, manganese oleate 
precursor was decomposed to form MnO and the monomer concentration would rise 
rapidly. As such, during the first 60 min of ageing, the size distribution is narrowed 
from 26.1% to 8.6%. Yet, over the next 120 min, the monomer concentration is 
depleted gradually and MONs would eventually lose its monodispersity due to the 
expected Ostwald ripening. 
 
4.3.4 Formation of hollow morphology 
 
Upon synthesis of the MONs, the nanocrystals can be further etched into their hollow 
counterparts in the presence of TOPO and alkylphosphonic acid. It is expected that 
such a hollow morphology can enhance the r1 relaxivity due to an increased Mn2+ 
concentration exposed at the hollow inner surface. Hollow MONs have also been used 
as nanoreactors for selective catalytic reactions. 
 
Figure 4.8 shows TEM images of the hollow MONs synthesized from spherical solid 
MONs. The process of nanoscale etching can be attributed to the Kirkendall effect,[8] 
which arises due to the outward diffusion of Mn atoms balanced by the inward 
diffusion of vacancies into the solid. This results in the formation of a void within the 
core. 
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The present study demonstrated the successful facile synthesis of monodisperse 
MONs by the thermal decomposition of a manganese oleate complex in high boiling 
non-polar solvents. Due to the binding of oleate ligands to the nanoparticle surface, 
the MONs are stable in air and will not be oxidised from Mn2+ to Mn3+ readily.  
 
In addition, control of the particle size has been achieved by manipulating the type of 
solvent, reaction time and reaction temperature. Following the successful synthesis of 
MONs for incorporation into the PEOSNs, we envisage that the nanocarriers can 
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Chapter 5 
ENCAPSULATED MANGANESE OXIDE 
NANOPARTICLES FOR HIGH PERFORMANCE 




MRI is a non-invasive medical imaging modality that provides excellent soft tissue 
contrast for anatomical imaging with high spatial resolution. For T1-weighted MRI, 
GBCAs are commonly used. However, these GBCAs are contraindicated in patients 
with renal disease or liver transplant due to the increased risk of nephrogenic systemic 
fibrosis.[1] Hence, there has been great impetus for developing alternative MRI T1-
contrast agents. In this regard, manganese (Mn) and its derivatives have appeared as 
promising replacements, owing to the reduced toxicity and comparable positive 
contrast when compared to Gd3+ ions.[2] 
 
The seminal publication first describing the use of MONs as T1 contrast agents for 
MRI was reported by Hyeon and co-workers.[3] Compared to commercially available 
Mn2+ chelates (e.g. Teslascan®) for MRI, it was proposed that the MONs would be 
preferred, as they offer a large payload of MR-active magnetic centers.[4] This 
groundbreaking work has successfully demonstrated the application of MONs as a T1 
contrast agent in the mouse brain. Nonetheless, the maximum specific relaxivity (r1) is 
restricted by the use of a PEG-phospholipid coating to encapsulate the MONs, which 
inevitably reduces the accessibility of water molecules to the MnO core.[5,6] Therefore, 
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there has been a strong ongoing pursuit to engineer MONs and their encapsulation for 
higher r1 relaxivity. 
 
Modifying the particle size and morphology of MONs has a profound effect on the r1 
relaxivity. For example, Huang et al.[2] observed that nanoplates showed the largest r1 
relaxivity amongst the different nanostructured morphologies of MONs. Hyeon et 
al.[3] also showed that the r1 relaxation rate increased as the particle size of MONs 
decreased. Shin et al.[7] reported that the hollow MONs could exhibit a higher r1 
relaxivity than those of their solid counterparts due to a higher surface-to-volume 
ratio. Nevertheless, it still remains a challenge to develop an ideal nanocoating shell 
for the encapsulation of these hydrophobic payloads. 
 
Ideally, the nanoshell should fulfill the following desirable functions for MRI: i) 
render the MONs biocompatible, water-dispersible and colloidally stable in 
physiological environment, ii) be sufficiently thin so that the overall diameter remains 
between 5 and 100 nm; such dimension ensures a prolonged blood circulation and 
reduced opsonization, iii) allow the encapsulated manganese paramagnetic cores to 
interact readily with the surrounding water molecules for higher r1 relaxivity, and iv) 
prevent Mn-ion leaching in order to avoid toxic accumulation of Mn2+ in tissues. 
However, to the best of our knowledge, none of the encapsulation strategies used at 
present has been demonstrated to satisfy all of these criteria. 
 
Although the PEG-phospholipid coating has been the most widely used strategy thus 
far to functionalize MONs, its efficiency for water exchange is the subject of much 
debate.[5,6] Similarly, poly(lactic-co-glycolic acid) has been used to encapsulate 
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MONs. However, the intact nanoparticles demonstrated a very low r1 relaxivity of 
0.21 mM-1s-1 under physiological pH.[8] It has been argued that the use of a more 
hydrophilic encapsulation material can potentially increase the exchange rate of water 
molecules, thereby shortening the T1 relaxation time. As a proof-of-concept, Chen and 
co-workers[5,6] encapsulated MONs with either human serum albumin or polyaspartic 
acid. Using a 7.0 T MRI scanner, both coating materials exhibited a high r1 relaxivity 
of 1.97 and 1.27 mM-1s-1 respectively. It was however conceded that the human serum 
albumin coated MONs lacked colloidal stability due to their tendency to precipitate 
upon prolonged storage.[6] Meanwhile, negatively-charged polyaspartic acid coated 
MONs exhibit a low blood circulation half-life as the electrostatic interactions would 
favour the binding of opsonins to the nanoparticle surface.[9] 
 
Another popular approach for the surface modification involves the use of polymeric 
ligands conjugated with dopamine moieties to yield highly water-soluble 
multifunctional MONs.[10,11] A major limitation of this strategy is however the 
susceptibility of the MnO core to degrade in aqueous solution over time. A 
comparative study has suggested that silica encapsulated MONs are a better 
alternative to prevent Mn-ion leaching.[12] This approach is supported by Lee and co-
workers,[13] who demonstrated that amongst a number of encapsulating materials 
tested in vitro, silica encapsulation favored the slowest dissolution rate of the MnO 
core in PBS solution. 
 
Unfortunately, it has also been shown that the formation of a silica nanoshell via the 
conventional reverse (water-in-oil) microemulsion technique often results in a dense 
silica framework that would limit the accessibility of water molecules to the MnO 
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core.[3,12,14] Therefore, mesoporous silica has been proposed as a viable solution to 
improve the r1 relaxivity,[15,16] Nevertheless, cetyltrimethylammonium bromide, which 
was employed to generate the mesopores, is highly toxic. Therefore, any incomplete 
removal of the surfactant can impede their use for biomedical applications. 
 
In order to address the various drawbacks of the encapsulation strategies outlined 
previously for MONs, we hereby proposed the use of PEOSNs as outlined in Chapter 
3. Firstly, the F127 block copolymer is chosen due to its high hydrophilicity and 
proven biocompatibility. Secondly, the incorporation of a nano-silica framework not 
only serves to reinforce the F127 micellar coating, but also to protect the MnO core 
from ion leaching. Thirdly, the silica-F127 nanohybrid coating is fabricated by the 
interfacial templating technique mentioned in the previous chapter, whereby the sol-
gel synthesis of the silica nanoshell is performed under room temperature and without 
the use of an alkaline catalyst.[17] This ensures the formation of a thin and highly 
permeable silica nanoshell that is perforated by the PEO chains of F127, thereby 
enhancing the accessibility of water molecules to the MnO core. Fourthly, unlike other 
designs of silica encapsulated MONs, our bilayer encapsulated MONs exhibit a nano-
rattle structure, wherein the MnO core is not in direct contact to the peripheral silica 
nanoshell. Hence, the passage of water molecules to the core interior is not blocked, 
since the hydroxyl groups on MnO surface are not involved in the sol-gel process.[16]  
 
In this chapter of the present study, we describe a detailed investigation into the 
encapsulation of MONs with the silica-F127 nanohybrid coating of PEOSNs and 
evaluate its efficacy as T1 MRI contrast agent. 
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5.2 Experimental Details 
5.2.1 Materials 
 
Block copolymer Pluronic® F127 (PEO106PPO70PEO106), TMOS (98%), THF, 1-
octadecene (technical grade, 90%), manganese (II) tetrahydrate (99%), oleic acid and 
pyrene were purchased from Sigma Aldrich. CellTiter 96 AQueous Non-Radioactive 
Cell Proliferation Assay MTS was procured from Promega. Fetal bovine serum (FBS) 
was obtained from Hyclone. Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing glucose, sodium pyruvate, L-glutamin, penicillin, and streptomycin were 
purchased from PAA Laboratories GmbH, Austria. 10× PBS was obtained from 1st 
Base and 1× PBS was prepared by diluting the 10× PBS with Milli-Q deionized water. 
All chemicals were used as received without any further purification. 
 
5.2.2 Synthesis of MONs 
 
In accordance to previously published reports,[18] the preparation of manganese oleate 
precursor and MONs have been described in Chapter 4. Briefly, the MONs were 
synthesized by the thermal decomposition of manganese oleate precursor dissolved in 
1-octadecene at elevated temperatures. The as-synthesized MONs were dispersed in 
THF to produce a stock solution of 20 mg/mL. 
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5.2.3 Synthesis of PEOMSNs 
 
Firstly, 15 mg of F127 was dissolved in 450 μL of THF.  450 μL of the MnO stock 
solution and 20 μL of TMOS were then added and stirred for 2 hours at room 
temperature to obtain a homogeneous mixture. Next, the mixture solution was slowly 
injected into 10 g of deionised water while being stirred rapidly. Stirring was 
continued for an additional 4 days to ensure complete hydrolysis of TMOS. The 
resulting aqueous dispersion was dialyzed against deionised water to remove any 
unreacted silica precursors. Empty silica nanocapsules were then removed by 
centrifugating at 6000 rpm, discarding the supernatant and re-dispersing the 
nanoparticles in deionised water. The final concentration of the purified PEOMSNs 




The MONs were characterized by following the procedure described in Chapter 4. 
TEM (JEM-2010F, 200 kV) was used to study the morphology of the synthesized 
PEOMSNs. DLS (Malvern Zetasizer Nanoseries) was performed using a HeNe laser 
(633 nm) to measure the particle size and distribution in solution. FT-IR (Varian 3100 
Excalibur) and X-ray photoelectron spectroscopy (XPS, ESCALAB 220I-XL Thermo 
Scientific) were employed to determine the chemical composition of PEOMSNs. ICP-
AES was used to determine the manganese concentration in the as-synthesized 
PEOMSNs. UV-vis-NIR absorption spectroscopy (Shimadzu UV-3101 PC 
spectrometer) was utilized to measure the controlled release kinetics of pyrene-
encapsulated PEOMSNs. 
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5.2.5 Antifouling study 
 
PEOMSNs were incubated in PBS containing 10 % (v/v) FBS at 37°C in a water bath. 
Their hydrodynamic sizes were measured by DLS at regular time intervals during the 
24 hours incubation in order to determine the degree of protein adsorption onto the 
surface of PEOMSNs.[19] As for the control, the hydrodynamic size of silica-coated 
MONs incubated in PBS/FBS solution was monitored using DLS. The silica-coated 
MONs were synthesized by repeated extraction of PEOMSNs with ethanol at 60°C to 
remove the F127. 
 
5.2.6 Mn2+ ion-leaching experiments 
 
Aqueous PEOMSNs solution was first divided into several equal aliquots, each of 
which was then allowed to incubate at room temperature. At each 5 days interval, one 
aliquot was selected for ultracentrifugation and the supernatant was analysed by ICP-
AES for Mn content. The likelihood of Mn2+ ion-leaching from MONs was quantified 
by monitoring the variation of Mn concentrations in the supernatants over an extended 
period of time.[3] 
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5.2.7 Control release experiments 
 
The pyrene-encapsulated PEOMSNs were prepared by the interfacial templating 
scheme as described above. Briefly, 2 mg of pyrene was dissolved in the homogenous 
mixture of MONs/F127/TMOS/THF prior to injection into the deionized water. The 
resulting mixture was kept stirring for four days at room temperature. Excess pyrene 
molecules were removed by centrifugation at 6000 rpm for 10 min. The as-prepared 
pyrene-encapsulated PEOMSNs in the supernatant were then transferred to a dialysis 
tube and immersed in an aqueous media at 37°C to monitor the release profile of 
pyrene. At regular time intervals, small aliquots of the aqueous media were removed 
subsequently for UV-vis measurements and replaced with fresh deionized water. 
 
5.2.8 Cell culture and cytotoxicity assay 
 
MTS assay was performed to assess the cytotoxicity of PEOMSNs. Briefly, MDA-
MB-231 cells obtained from ATCC were seeded into a 96-well plate at a density of 
8000 cells/well in the presence of growth medium. The culture medium contains 
completed DMEM with glucose (4.5 g/g), sodium pyruvate and L-glutamin, 10 % 
FBS, penicillin and streptomycin. Next, various concentrations of PEOMSNs were 
added to the cells and incubated at 37°C in 5% CO2. After 24 hours, the growth 
medium was discarded and replaced by MTS/phenazine methosulfate solution. The 
plate was further incubated for another 3 hours. Finally, the cell viability was 
quantified by using a Benchmark Plus microplate spectrophotometer (Bio-RAD) to 
measure the optical absorbance of each well at absorbance wavelengths of 490 nm. 
All samples were assayed in triplicate. 
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5.2.9 MRI relaxivity measurement 
 
MR relaxivities of the PEOMSNs were evaluated by using a 7-Tesla Bruker Clinscan 
MRI system in Singapore Bioimaging Consortium (SBIC). The T1 relaxation times 
were determined from an inversion recovery experiment with a number of TI 
(inversion time) (10 TIs; TI: 100–7000 ms; echo times (TE): 12 ms). T2 relaxation 
times were determined from a multi-echo spin-echo sequence (repetition time (TR): 
3000 ms; TE: 6.7–214.4 ms). The longitudinal (r1) and transverse (r2) relaxivities were 
obtained from the slope of 1/T1 or 1/T2 versus molar [Mn] concentrations plots. 
 
5.2.10 In vitro MRI study 
 
MDA-MB-231 cells were grown in a 8-well chamber at a density of 15,000 cells/well 
by using the same cell culture condition mentioned above. After 24 hours of 
incubation, the culture medium was replaced by fresh DMEM containing PEOMSNs 
at various concentrations. After another 24 hours of incubation in the presence of the 
nanoparticles, each well was washed with PBS for three times. The cells were then 
transferred into a 0.2 mL eppendorf tube and fixed with 4% paraformaldehyde 
solution. MR imaging of the MDA-MB-231 cells were then obtained by using a 7.0 
Tesla MR scanner (Bruker Clinscan system). Prior to imaging, a phantom was 
prepared by centrifuging the cells in the eppendorf tube at 400 G for 5 minutes. Each 
tube was then placed inside a 50.0 mL centrifuge tube, which was subsequently filled 
with 1% agarose solution. A spin echo sequence was optimized to generate T1-
weighted images of the MDA-MB-231 cells, the relevant acquisition parameters 
being, TR/TE = 400/12 ms, Number of averages (NA) = 4. 
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5.3 Results and discussion 
5.3.1 Preparation and physical characterization of PEOMSNs 
 
Scheme 5.1 An illustration of: (a) the synthesis of PEOMSNs; and (b) 3D-structure of a single MON 
encapsulated within the nanohybrid coating.  
 
An outline for the synthesis of PEOMSNs is illustrated in Scheme 5.1. Hydrophobic 
MONs with an average particle size of 16 nm were selected for further investigation. 
As has been described in Chapter 4, phase purity and high crystallinity of MONs was 
confirmed by XRD (Figure 4.4a), while FT-IR revealed the presence of oleyl surface 
ligands, which enable the MONs to remain stable against aggregation and oxidation 
(Figure 4.2). 
 
TEM image (Figure 5.1b) shows that the majority of the as-synthesized PEOMSNs 
are composed of individual MONs encapsulated within a PEO/SiO2 nano-rattle 
structure. This nanohybrid coating is carefully engineered by confining the silica shell 
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formation to the core-corona interface of F127 micelles. Hence, the free PEO chains 
perforated through the silica shell to form an outer periphery, whilst rendering the 
MONs water-dispersible and biocompatible. Although the PEO chains could not be 
observed in the conventional TEM image due to their low electron density, their 
presence on the surface of PEOMSNs was confirmed with DLS, which indicated a 
hydrodynamic size of 76.4 nm (Figure 5.1c). This was larger than the particle size 
derived from TEM (45 ± 4 nm), because the light scattering measurement included the 
contribution of the PEO chains extended in solution.[17] 
 
Figure 5.1 TEM images of: (a) ‘naked’, and (b) PEO/SiO2-coated MONs. (c) Hydrodynamic size 
distribution of PEOMSNs, measured by DLS. The average hydrodynamic diameter was determined to 
be 76.4 nm. (d) Wide-scan XPS spectrum of the as-prepared PEOMSNs. The inset shows a high-
resolution XPS scans of the Mn 2p region. 
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In addition, the nanorattle structure of PEOMSNs was re-confirmed by XPS, which 
indicated the presence of Si2s, Si2p and the comparatively weaker Mn2p peaks (Figure 
5.1d). Since XPS is a surface-sensitive technique, this suggests that the MONs are 
well-encapsulated within the core interior, thereby resulting in a limited ability of XPS 
to detect these structures. It also confirms the chemical stability of MONs because the 
high resolution XPS scans of the Mn2p region corresponds closely to the standard 
spectra of bulk MnO. Hence, it shows that Mn2+ is not readily oxidised to the higher 
valence states despite being stored in air for several days. 
 
Formation of the nano-rattle structure is achieved by using the interfacial templating 
technique in the present work, wherein the silica precursor (TMOS), hydrophobic 
MONs and the block copolymer F127 are simultaneously introduced into the aqueous 
solution. During the micellization process, TMOS and MONs are first sequestered 
into the hydrophobic core of F127 micelles; subsequent hydrolysis and condensation 
of TMOS in the interfacial region between the PPO core and PEO corona thus prevent 
the MnO core from being in direct contact to the peripheral silica nanoshell. 
 
Moreover, FT-IR analysis indicates that the vibration band intensities of oleyl surface 
ligands have decreased significantly upon encapsulation (Figure 5.2a). Instead, a 
strong and broad absorption band appears in the region of 1000 - 1200 cm-1. This is 
attributed to the superposition of multiple peaks belonging to both silica and F127:  
asymmetric O–Si–O stretching vibrations (1097 cm-1) and the typical triplet of intense 
overlapped bands in the C-O-C stretching region of F127.[20] Hence, a successful 
exchange of the hydrophobic oleate ligands by the nanohybrid F127/SiO2 coating 
layer in PEOMSNs has taken place. The presence of MONs in PEOMSNs is also 
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reflected by the absorption bands of the Mn-O bond (623 cm-1, 511 cm-1). This is 
further verified by the XRD trace of PEOMSNs (Figure 5.2b), which shows the 
evaporation-induced crystalline peaks of F127,[20] as well as the (111), (200) and (220) 
peaks of MnO. 
 
Figure 5.2 (a) FT-IR spectra; and (b) XRD patterns of ‘naked’ and PEO/SiO2-coated MONs. 
 
5.3.2 Stability study of PEOMSNs 
 
Biostability and biocompatibility are two essential prerequisites for biomedical 
applications of MRI contrast agents. In order to evaluate the colloidal stability of 
PEOMSNs upon systemic administration, we have investigated the nanoparticles for 
their behavior in non-specific protein adsorption and mechanical stability under 
extreme dilution conditions. The former is demonstrated by incubating PEOMSNs in 
a PBS solution containing 10% FBS at 37°C. DLS was then used to monitor the 
changes in the hydrodynamic diameter of the nanoparticles. 
 
Ideally, the PEO segment of the nanohybrid coating layer should enhance the water 
solubility, while reducing non-specific protein adsorption. This is evidenced in Figure 
5.3a, where it can be observed that there is no significant change in the hydrodynamic 
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diameter of PEOMSNs upon incubation in PBS containing 10% FBS. It also suggests 
that particle agglomeration has been avoided, since the FBS proteins do not readily 
adhere to the nanoparticles. In contrast, when the PEO corona is removed by ethanol, 
there is a marked increase in the DLS size after 12 hours of incubation. Therefore, 
these experimental results demonstrate that the free PEO chains trail on the surface of 
PEOMSNs, and confer antifouling properties by preventing particle agglomeration 
due to the non-specific binding to protein. 
 
Meanwhile, the F127 micelles alone did not provide sufficiently stable dispersion due 
to their susceptibility to disruption once below the critical micelle concentration. This 
is observed in Figure 5.3b, which shows a marked increase in the hydrodynamic 
diameter of F127-encapsulated MONs when the dilution factor is 2. However, the 
onset of particle agglomeration for PEOMSNs is significantly diminished until 
extreme dilution conditions (200 times). This suggests that silica plays an important 
role in reinforcing the F127 micellar structure and our selection of a silica/F127 
nanohybrid coating would favour a synergistic improvement in the biostability of 
MONs. 
 
Figure 5.3 (a) Antifouling behaviour. Change in hydrodynamic diameter of nanoparticles measured as 
a function of time upon incubation in PBS containing 10 % FBS at 37°C. (b) Particle stability under 
dilution. DLS particle size change as a function of dilution factor. 
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5.3.3 Cytotoxicity study of PEOMSNs 
 
It is also essential to minimize the toxicity of nanoparticles. In this regard, PEOMSNs 
must not only be non-toxic to cells, the MnO core inside the silica shells should also 
be stable enough against Mn-ion leaching. Otherwise, a toxic accumulation of Mn2+ in 
tissues can result in hepatic failure and cardiac toxicity.[4] Hence, in the present study 
two tests were conducted to evaluate the cytotoxicity of PEOMSNs. 
 
Firstly, a MTS assay was performed to evaluate the viability of MDA-MB-231 cells, 
which were incubated with varying concentrations of PEOMSNs for 24 hours. Figure 
5.4a shows that the PEOMSNs are relatively non-cytotoxic as a high cell viability 
(83%) can be maintained even at a concentration of 224.9 μM Mn. Secondly, the 
likelihood of Mn-ion leaching is quantified by monitoring the variation in Mn 
concentrations of supernatants after centrifugation at regular 5-day intervals (Figure 
5.4b). As ICP-AES indicates no substantial increase in the Mn content from the 
supernatants despite an incubation period of 30 days, it suggests that the highly stable 
MnO core is not susceptible to appreciable leaching-out over an extended time period. 
 
Figure 5.4 (a) MTS assay of MDA-MB-231 cells. Cells were incubated with different concentrations of 
PEOMSNs for 24 hours. (This work is done in collaboration with Dr. Wang Miao.) (b) Mn-ion leaching 
experiments. The increase in Mn content of the supernatant of PEOMSNs was determined over time. 
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5.3.4 Permeability of nanohybrid coating 
 
A high r1 relaxivity is favoured with improved accessibility of water molecules to the 
paramagnetic MnO core. In this regard, MONs are able to exert a more efficient water 
exchange if the silica framework is highly permeable, thin and hydrophilic. Yet, the 
conventional means to form the silica nanoshell would typically result in a dense 
silica framework.[12,14] 
 
In order to demonstrate the highly permeable nature of the nanohybrid encapsulating 
layer developed in the present study, the PEOMSNs were dispersed in an acetate 
buffer solution (pH 5.0) and stirred for 16 hours to etch away the MnO core. Figure 
5.5a shows the formation of an interior void in the encapsulated MONs when 
subjected to such acidic conditions, thereby suggesting that the acidic solution can 
penetrate readily through the PEO/SiO2 hybrid coating to bring about a gradual 
dissolution of MONs. A hollow interior is subsequently formed and this verifies the 
porosity of the silica shell, which is successfully engineered in this manner via the 
interfacial templating scheme, whereby the hydrolysis and condensation of silicon 
alkoxides are confined to the interfacial region between the core and corona of the 
F127 micelles. As a result, the silica nanoshell formed is perforated with PEO chains, 
which can act as hydrophilic nanochannels for the rapid penetration of water 
molecules to MnO core. 
 
Moreover, the interfacial templating scheme is specifically conducted at room 
temperature and without the use of an alkaline catalyst (e.g. ammonia). This favours 
the formation of a low-density silica framework that can still remain intact despite a 
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12-hour acidic immersion. Therefore, the MnO payloads encapsulated in the nanocore 
will not be prematurely released into the surroundings because the PEO/SiO2 
nanohybrid coating is chemically stable to moderate pH changes. 
 
Figure 5.5 (a) TEM images of PEOMSNs after 16-hours acidic etch in an acetate buffer solution. The 
formation of hollow cavities within the encapsulated MONs is observed. (b) UV-vis absorption spectra 
at different time periods of the aqueous media in which pyrene was released from the pyrene-
encapsulated PEOMSNs. 
 
Pyrene was also selected as a model drug to evaluate the controlled release behaviour 
of PEOMSNs. This was achieved by the simultaneous encapsulation of pyrene and 
MONs within the silica-F127 hybrid nanocapsules, which is likely facilitated by the 
nano-rattle structure of PEOMSNs. The controlled release of pyrene by PEOMSNs 
was monitored by UV-vis absorption analysis (Figure 5.5b). From the increasing 
absorption intensity of the peak at ca. 275 nm, it indicates that the pyrene content is 
gradually released into the surrounding aqueous media with time. Therefore, it 
provides further verification of the highly permeable nature of the silica-F127 
nanohybrid coating. 
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5.3.5 Magnetic resonance behaviour of PEOMSNs 
 
In order to illustrate the enhancement in T1 contrast as afforded by the porosified 
PEO/SiO2 nanocoating, the relaxation times of aqueous PEOMSNs solution were 
measured on a pre-clinical 7.0 T MRI scanner. Figure 5.6a shows the T1- and T2-
weighted phantom MR images at different Mn concentrations. Clearly, its potential to 
function as a MRI contrast agent is confirmed as the image contrast is significantly 
enhanced with a minute change in concentration. The specific relaxivities (r1 and r2), 
derived from the plots of 1/T1 and 1/T2 versus Mn concentration (Figure 5.6b), were 
determined to be 1.17 and 30.73 mM-1s-1, respectively. Compared to the other 
commonly used surface coatings of MONs, there is indeed an increase in the r1 
relaxivity of MONs if all other factors remain unchanged. For example, the r1 value 
for non-hollow MONs of 15 nm in size, is reported to be 0.11, 0.08 and 0.65 mM-1s-1, 
when encapsulated with a PEG-phospholipid, dense silica and mesoporous silica 
coating, respectively.[15] 
 
For the same concentration range, the PEOMSNs developed in this work are also able 
to exhibit substantial contrast on the T2-weighted images, thus it can function as a 
suitable T1-T2 dual mode MRI contrast agent. This has apparent advantages in clinical 
settings, as the T1-weighted images can be used to highlight the anatomy, while the 
T2-weighted images are more suited for the identification of pathology.[21]  
 
Finally, Figure 5.6c confirms the effectiveness of PEOMSNs to function as a MRI 
probe for cell labelling. When MDA-MB-231 cells were incubated with PEOMSNs, 
the nanoparticles could be successfully internalized by the cancer cells to give a 
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concentration-dependent signal enhancement in the corresponding T1-weighted 
images. 
 
Figure 5.6 (a) T1- and T2-weighted MR images of PEOMSNs at various Mn concentrations in water. (b) 
Plot of 1/T1 and 1/T2 versus Mn concentration. The slope indicates the corresponding specific 
relaxivities r1 and r2. (c) T1-weighted MRI images of MDA-MB-231 cells incubated with PEOMSNs at 
various concentrations for 24 hours. (This work is done in collaboration with SBIC.) 
  




We have successfully encapsulated MONs into PEOSNs. Following the interfacial 
templating scheme, the nanohybrid coating layer thus developed consists of a thin and 
porosified silica nanoshell, which is perforated by the PEO chains of F127 on surface. 
Besides a synergistic improvement in the colloidal stability of MONs, the nanohybrid-
encapsulated MONs demonstrate a relatively high T1 relaxivity due to the improved 
accessibility of water molecules to the MnO core. 
 
The biocompatibility of these PEOMSNs is confirmed by MTS assay, while ion-
leaching experiments suggest that they are not liable to Mn-ion leaching. The unique 
nanorattle structure of PEOMSNs not only improves the passage of water molecules 
into the MnO core, it would also allow for the facile loading of therapeutic reagents 
for theranostic applications, which is demonstrated by the controlled release of 
encapsulated pyrene as a model drug. 
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Chapter 6 
NANOREACTOR FOR NANOSCALE ETCHING OF 




In 2007, Hyeon and co-workers published their seminal work describing the use of 
MONs as T1 contrast agents for MRI.[1] Since then, this new class of MRI contrast 
agent has opened a new direction for exploring various strategies to engineer MONs 
of higher r1 relaxivity. In this regard, modifying the particle size and morphology of 
MONs has been shown to have a significant effect on the r1 relaxation rate. In general, 
the r1 relaxivity is expected to increase as the particle size of MONs decreases. For 
example, Chen et al. observed that MONs with a size of 10 nm exhibited a greater 
positive contrast ability than those with larger sizes.[2] Hollow-structured MONs are 
also attractive candidates as T1 contrast agents because they exhibit high surface-to-
volume ratio. Since only the surface Mn2+ ions in a nanoparticle are largely 
responsible for the longitudinal water proton relaxation, these hollow MONs tend to 
exhibit higher r1 relaxivities than those of their solid counterparts. Herein, there has 
been a burgeoning interest to use hollow MONs as a platform to build an integrated 
MRI diagnostic and therapeutic nanoprobe for various types of cancers.[3-7] 
 
There are a number of synthesis protocols that have been developed to produce the 
hollow cavities of MONs. Typically, they involve the selective core removal of pre-
synthesized MONs by using a suitable etchant. Lee and co-workers used phthalate 
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buffer solution at pH 4.6 to form the voids in the core of MONs.[3] Similarly, Gilad et 
al. employed mild hydrochloric acid solution at pH 2.4 to extrude the hollow core of 
MONs.[4] Such approaches were successful due to a compositional difference between 
the core and shell of MONs. As a result, the hollow interior is created by a preferential 
dissolution of the MnO core phase and the stability of the Mn3O4 shell phase under 
acidic conditions. Alternatively, a hydroxylamine (NH2OH) dispersion, which is 
known to form complexes with metal ions readily, has been demonstrated to be 
effective in the selective etching of MnO core from a sacrificial template of MnO-
Mn3O4 core-shell nanoparticles, thus yielding well-defined hollow MONs.[8] 
 
Apart from the composition difference-based selective etching strategy, the nanoscale 
Kirkendall effect is another method that is commonly used to produce hollow MONs. 
It provides a mechanism for void formation in inorganic nanoparticles because the 
outward diffusion of Mn2+ ions is balanced by an inward flux of vacancies which 
would subsequently coalesce to form the hollow interior core. During the formation 
process, the surface layer of MONs is usually stabilized by surfactants or simple 
inorganic anions in the solution. This reduces the overall surface energies and 
promotes the spontaneous dissolution of the particle interiors. For example, Chou and 
co-workers have identified that the acetate anion is crucial to the structural evolution 
from solid to hollow MONs in their synthesis protocol, as it can function as a 
chelating ligand to remove the MnO core via the Kirkendall effect.[5] Hyeon et al. 
have also attributed their success of preparing hollow MONs to the Kirkendall effect, 
wherein the alkylphosphonic acid impurities in technical grade TOPO are able to bind 
strongly to the surface Mn2+ ions and drive the hollowing process of MONs.[9] 
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However, despite the recent advances in developing hollow MONs, there has been 
limited work done to tailor the architecture of hollow nanostructures. In fact, to the 
best of our knowledge, reports on the synthesis of hollow MONs are primarily 
focused on single particle encapsulation. In this regard, perhaps there is a notion that 
individually-encapsulated hollow MONs are able to induce the longitudinal water 
proton relaxation most efficiently. Otherwise, it may be challenging to control the size 
and uniformity of the encapsulation of hollow MONs clusters.[10] Therefore, it would 
be of interest, both technologically and scientifically, to establish a hybrid silica 
nanoreactor for the facile synthesis of well-defined hollow MONs, as detailed below.  
 
The framework itself is composed of a thin silica nanoshell that is perforated by the 
PEO chains of F127. Using these nanocontainers to encapsulate MONs, several key 
advantages become apparent: besides eliciting a relatively high r1 relaxivity due to an 
improved accessibility of water molecules to the encapsulated MON core, the 
nanoreactor framework can also provide the desired in situ surface modification by 
substituting the hydrophobic oleate ligands of MONs with highly hydrophilic PEO 
chains that resist reticuloendothelial system interactions.[11] Hence, the blood 
circulation time of MONs can be prolonged for better MRI visualization.[12] Indeed, 
such useful properties have been validated in our study, which demonstrated the 
excellent antifouling behaviour and high water permeability of the PEO-perforated 
silica nanoshell.[11] 
 
On the basis of this understanding, in the present study, the hybrid silica nanocapsules 
are developed as robust nanoreactors to prepare hollow MONs of various 
architectures (single or a cluster of core particles). Moreover, we demonstrate a novel 
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approach to increase the r1 relaxivities of MONs, wherein a moderate number of core 
nanoparticles are encapsulated to increase the rate of water exchange. Thus, this will 
favour further development of MONs as T1 contrast agents in clinical applications. 
 
6.2 Experimental Details 
6.2.1 Synthesis of MONs 
 
In accordance to previously published reports,[13] the preparation of manganese oleate 
precursor and MONs have been described in Chapter 4. Briefly, MONs of size 16 nm 
were produced by the thermal decomposition of manganese oleate precursor dissolved 
in 1-hexadecene solvent at at 280°C for 1 hour. 
 
6.2.2 Encapsulation of MONs in PEOSNs 
 
The interfacial templating scheme was employed to fabricate the hybrid silica 
nanoreactor.[11] For single MON encapsulation, 15 mg of F127 was first dissolved in 
450 μL of THF. 450 μL of the MONs stock solution and 20 μL of TMOS were then 
added and stirred to obtain a homogeneous mixture. Next, the mixture solution was 
slowly injected into 10 g of deionised water while being stirred rapidly. Stirring was 
continued for an additional 4 days to ensure complete hydrolysis of TMOS. The 
resulting aqueous dispersion was dialyzed against deionised water to remove any 
unreacted silica precursors. Finally, the encapsulated MONs were retrieved by 
centrifuging at 6000 rpm, discarding the supernatant and redispersing the solid residue 
in deionized water. A similar protocol was used for multiple MONs encapsulation 
except for the following differences: (i) To prepare nanoreactors with an average of 3, 
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5 and 10 MONs, 15 mg of F127 was first dissolved in decreasing volumes of THF 
(300, 150, 0 μL) respectively. Next, increasing volumes of MONs stock solution (600, 
750, 900 μL) were added accordingly so as to make up a total volume of 900 μL. (ii) 
In the case of nanoreactors with an average of 5 and 10 MONs, they were retrieved by 
centrifuging at 4000 rpm, discarding the supernatant and redispersing the solid residue 
in deionized water. The yield of nanoreactors with different number of MONs was 
determined based on a statistical assembly of 100 nanoparticles under TEM, which is 
illustrated in Table 6.1. 
 
Table 6.1 Preparation of nanoreactors with different number of MONs 
Avg. number 











1 450 450 6000 1 - 2 97b) 
3 600 300 6000 2 - 4 86c) 
5 750 150 4000 4 - 6 76d) 
10 900 0 4000 8 - 12 65e) 
 
a) Based on a statistical assembly of 100 nanoparticles under TEM; b) 97% of the nanoreactors have 
1 to 2 MONs encapsulated in its core; c) 86% of the nanoreactors have 2 to 4 MONs encapsulated 
in its core; d) 76% of the nanoreactors have 4 to 6 MONs encapsulated in its core; e) 65% of the 
nanoreactors have 8 to 12 MONs encapsulated in its core. 
 
6.2.3 Nanoscale etching of encapsulated MONs 
 
To form the desired nanohollow core structure of MONs, the encapsulated MONs 
were dialyzed against an acetate buffer solution (pH 5.2) at room temperature for 36 
hours. During this process, small aliquots of the sample solution were also extracted 
and analysed for their Mn contents by ICP-AES. The resulting nanohollow MONs 
were purified by repeated centrifugation and redispersion in deionised water. Finally, 
the solution was passed through a 0.20 μm filter to remove the presence of aggregates. 
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6.2.4 MRI relaxivity measurement 
 
MR relaxivities of the MONs and Magnevist® were evaluated by using a 7-Tesla 
Bruker Clinscan MRI system. T1 relaxation times were determined from an inversion 
recovery experiment with a number of TI (inversion time) (10 TIs; TI: 100–7000 ms; 
echo times (TE): 12 ms). The longitudinal (r1) relaxivities were obtained from the 
slope of 1/T1 versus molar concentration plots. 
 
6.2.5 In vivo MR imaging 
 
Briefly, 200 μL of 1% agarose and 0.40 mM of MONs (fixed with agarose) were 
injected into the left and right flanks of a nude (nu/nu, Balb/c) mouse respectively. 
The mouse was placed in a 7-Tesla Bruker Clinscan MRI system under 
anesthetization by inhalation of isoflurane. The T1-weighted images were acquired 
with the following acquisition parameters: repetition time (TR) and echo time (TE), 
TR/TE = 526.0/8.9 ms, with 8 averages and field of view (FOV) = 40 mm. Animal 
experiments were performed in accordance with the Institutional Animal Care and 
Use Committee (IACUC) guidelines under ethics number IACUC 120748. 
 
6.2.6 Cytotoxicity study 
 
The Alamar blue assay was performed to assess the cytotoxicity of hollow MONs 
with multiple 16-nm cores. Briefly, HeLa cells obtained from ATCC were cultured on 
a 96-well plate at a density of 6000 cells/well. After 24 hours, fresh culture medium 
containing MONs with concentration range of 0 – 480 μg/mL was added. The cells 
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were incubated with the nanoparticles at 37°C in 5% CO2 for 12 hours, then rinsed 
and replaced with fresh culture medium. Alamar blue reagent was added to each well 
at a concentration of 10% (v/v) and the cells were incubated for an additional 4 hours. 
This was followed by the spectrophotometric analysis using a Fluoroskan Ascent FL 
spectrophotometer (Thermo Labsystems). Cell viability was expressed as a percentage 
of the untreated control cells. 
 
6.3 Results and discussion 
6.3.1 Nanoreactor synthesis of hollow MONs 
 
Scheme 6.1 Schematic illustration for the synthesis of hollow MONs. 
 
Scheme 6.1 shows an outline for the preparation of hollow MONs using our 
nanoreactor platform. Interfacial templating condensation of TMOS in the core-shell 
region of F127 micelles was employed to fabricate the hybrid silica nanoreactor.[11] 
Herein, in order to provide a direct comparison with earlier reports on hollow MONs, 
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which typically range from 15 to 20 nm in sizes, we chose the 16 nm-sized MONs for 
encapsulation into the hybrid silica nanoreactors. Next, to form the hollow core of 
MONs, an acidic acetate buffer solution (pH 5.2) was employed as the etchant under 
standard temperature and pressure. This is crucial to generate the well-defined hollow 
morphology of MONs. The versatility of this method is demonstrated by the facile 
synthesis of hollow MONs with varying encapsulation morphologies. 
 
6.3.2 Designing MONs of higher r1 relaxivity 
 
There are three key advantages in employing the nanoreactor platform for the 
development of hollow MONs. Firstly, by employing the interfacial templating 
technique, hydrolysis and condensation of silica precursors are confined to the 
interface between the PPO core and PEO corona of the polymeric micelles. Hence, the 
nanoreactors are composed of a thin silica shell that is perforated with PEO chains 
(Figure 6.1), which enable them to maintain the structural integrity and aqueous 
dispersity in the etchant solution for a prolonged duration of time. This is in contrast 
to other designs of silica-coated hollow MONs, which tend to require the direct 
coating of a thick silica layer onto the MONs prior to nanoscale etching.[4-5,8] Such 
enhanced stability of the framework is attributed to its nanocomposite-type structure, 
where the inorganic silica fractions yield mechanical strength and the hydrophilic 
PEO chains provide good anti-fouling properties. 
 
Secondly, the silica nanoreactor provides a high degree of control over the hollow 
nanostructure of MONs as it ensures that the etching chemistry is done in a confined 
volume under the controlled conditions and selective permeability. This is due to the 
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controlled diffusion of etchant molecules through the PEO-based polymer 
nanochannels that perforated through the silica shell. The permeability of the silica 
shell is confirmed by the subsequent diffusion of Mn2+ ions from the nanoreactor 
during etching, which is elaborated further in the later section. 
 
Figure 6.1 TEM images of the hollow MONs with: (a) single 16-nm core; and (b) multiple 16-nm cores. 
(c) 3D-illustration of the hybrid silica nanoreactor framework. 
 
Thirdly, due to the employment of F127 polymeric micelles as soft templates to form 
the silica shell, the dimensions of the nanoreactor construct can be facilely altered in 
accordance to the number of encapsulated MONs. This allows for a systematic 
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investigation into the nanocomposite architecture in order to engineer MRI contrast 
agents of higher r1 relaxivity. There are two parameters that are varied in the present 
work: (i) MON core morphology (solid vs hollow nanoparticles); and (ii) Number of 
MONs (single vs multiple nanoparticles). Table 6.2 shows the r1 relaxivities of the 
samples. Plots of the T1-1 versus Mn concentration for the hollow MONs are detailed 
in Figure 6.2a. 
 
Table 6.2 r1 relaxivities of MONs with different nanostructures 
Core Size [nm] Core Morphology No of core particles r1 value [mM-1s-1] 
16 Hollow Multiplea) 2.58 
16 Hollow Singleb) 1.23 
16 Solid Multiple 2.22 
16 Solid Single 1.17 
 
a)Average number of MnO cores (2 or more); b)Average number of MnO cores (1 to 2) 
 
 
Figure 6.2 (a) Plots of T1
-1 versus Mn concentration for the hollow MONs of various nanostructures. 
(b) Plots of T1
-1 versus Gd concentration for clinical Magnevist®. The corresponding r1 relaxivity is 
defined by the slope of the as-determined straight line. (This work is done in collaboration with SBIC.) 
 
The relaxivity measurements indicate that the formation of a hollow interior is indeed 
a useful strategy to enhance the r1 relaxivity of MONs. This can be explained by the 
increased concentration of surface Mn ions that is exposed to water molecules in the 
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inner surface.[3,4] Interestingly, there is also a consistent increase in the r1 relaxivities 
of MONs if there is a cluster encapsulation of core particles. In fact, among all of the 
various architectures of MONs, the hollow MONs with multiple 16-nm cores exhibit 
the highest r1 relaxivity of 2.58 mM-1s-1 (Table 6.2). This r1 value is more than a two-
fold increase when compared to that of the hollow MONs with only a single 16-nm 
core, as reflected in their corresponding T1-weighted images (Figure 6.3a). 
 
Figure 6.3 (a) T1-weighted MR images of the hollow MONs with different numbers of core particles. (b) 
T1-weighted image of a mouse with subcutaneous injection of 1% agarose (site a) (reference) and 
hollow MONs in 1% agarose (site b). (This work is done in collaboration with SBIC.) 
 
Although the relaxivity is lower when compared to commercial T1 reagents 
(Magnevist®, Gd-DTPA), which exhibits a r1 value of 5.33 mM-1s-1 at 7 T under the 
same testing conditions (Figure 6.2b), the new system represents an alternative class 
of T1 MRI contrast agents that offers lower toxicity and comparable imaging 
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performance, especially in view of the recent association of GBCAs with nephrogenic 
systemic fibrosis.[14,15] In vivo validation of the hollow MONs with multiple 16-nm 
cores is also conducted by a subcutaneous injection of the nanoparticles (0.40 mM) in 
the flank region of a mouse model (site b). A hyperintense region generated by the 
nanoparticles was observed in the transplantation site (Figure 6.3b), thus affirming 
their ability to function as highly efficient T1 MRI contrast agents. 
 
The T1 contrast enhancement as exerted by the cluster encapsulation can be explained 
by the rotational dynamics of MONs in the silica nanoreactor. Based on the Solomon-
Bloembergen-Morgan theory, proton relaxation in paramagnetic solutions is highly 
dependent on the effective correlation time of the contrast agent, which corresponds 
closely to the proton Larmor precession frequency for an optimal r1 relaxivity.[16,17] 
One method of modulating the effective correlation time is to control the rotational 
motion of the T1 contrast agent.[18] For example, the rapid molecular rotation of free 
chelated Gd can be markedly slowed down by means of conjugation to the surface of 
hollow nanometer-sized vesicles, thus achieving a higher r1 relaxivity.[19] 
 
In the present case, due to the higher particle packing density for the cluster 
encapsulation of MONs in the cavity of the silica nanoreactor, the rotational diffusion 
of surface Mn2+ ions of MONs is likely to be more restricted by the closer proximity 
and stronger interactions with the polar hydroxyl groups of the silica nanoshell. As a 
result, there is an increase in the rotational correlation time of the paramagnetic 
payload to a rate that more closely matches the proton Larmor frequency. In turn, this 
will induce a higher degree of T1 relaxation to the surrounding water protons for 
enhanced T1 MRI contrast. 
Chapter 6: Nanoscale Etching of Manganese Oxide Nanoparticles  
 119 
A systematic investigation into the degree of T1 contrast enhancement by samples with 
varying numbers of MONs was also conducted. The rationale of this study was to 
compare the measured relaxivities of each sample and determine if there is an ideal 
cluster size that corresponds to the optimal correlation time required to maximise the 
r1 relaxivity of our system. The increasing number of MONs of each sample was 
verified by TEM and DLS analysis (Figure 6.4). The relaxation times of each sample 
were also measured on a 7.0 T MRI scanner. Figure 6.4f shows that the highest r1 
relaxivity is achieved when a moderate number of ~3 MONs are encapsulated. 
Beyond this optimal cluster size, there is a gradual decrease in r1 relaxivity with the 
increasing number of core particles. Hence, these experimental results are in 
agreement with simulations which suggest that an intermediate rotational correlation 
time is required to maximize the r1 relaxivity at fields of 1.5 T or higher.[18] 
 
Figure 6.4 TEM images of the MONs prior to nanoscale etching, with (a) one; (b) three; (c) five; (d) 
ten core particles. The average number of core particles is based on the statistical assembly of 100 
nanoparticles under TEM and indexed to the nearest integer. (e) Hydrodynamic size distribution and (f) 
plot of 1/T1 versus Mn concentration for the MONs of different cluster sizes. (This work is done in 
collaboration with SBIC.) 
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In addition to the influence of correlation time, the paramagnetic relaxation 
enhancement of MONs can be divided into two different solvation spheres; namely 
inner and outer.[17] The inner sphere effect, which requires direct contact between the 
MONs and water molecules, is able to induce the proton relaxation rate more 
efficiently. Since the hybrid silica nanoreactor is able to allow water molecules to 
transverse through its PEO-perforated walls and interact directly with the MONs, the 
inner sphere relaxation is dominant and this accounts for the high r1 relaxivities of 
MONs. However, upon the encapsulation of an excess number of MONs (i.e. 10 
particles or greater), there is less available space in the interior cavity of the 
nanoreactor for water molecules to diffuse into. This reduces the number of water 
molecules that can come into close proximity to the MONs and diminishes the 
influence of inner sphere relaxation, thereby lowering the r1 relaxivity of MONs. 
 
6.3.3 Kinetics of hollow MON formation 
 
The evolution of core morphology with time was investigated to determine the etching 
mechanism in the nanoreactor framework. It is known that the Kirkendall effect 
should be reflected by an inward flow of vacancies to form voids, which tend to 
nucleate at the boundary due to its higher surface energy and defect content.[20,21] 
However, TEM images (Figure 6.5a) indicate an absence of Kirkendall intermediates 
with yolk-shell nanostructures. It is thus highly improbable that the nanoscale 
Kirkendall effect is responsible for driving the hollowing process in our system.  
 
Instead, the selective dissolution of the nanoparticle interior has occurred in a sporadic 
and random manner, while a thin edge wall of about 3 nm has remained intact during 
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the etching process, even after a prolonged etching duration of 48 hours which 
ultimately cause the nanoreactor framework to disintegrate. Our initial assumption is 
that the associated etching mechanism is due to a compositional difference between 
the core (MnO) and the shell (Mn3O4) of MONs.[11,22] However, XPS analysis has 
revealed that the oxidation state of MONs is relatively unchanged despite the core 
removal during etchant treatment (Figure 6.5b), thus it implies that the core and shell 
are likely to be of the same oxidation state. 
 
Figure 6.5 (a) TEM images of the MONs dispersed in acetate buffer solution at different stages of the 
nanoscale etching process. (b) High-resolution XPS scans of the Mn 2p region before and after the 
nanoscale etching process. (c) Evolution of the manganese content during the nanoscale etching of 
MONs. 
 
For controls, encapsulated MONs were also separately immersed in PBS and mild 
HCl solution (concentration diluted to ~ pH 5), but the resulting nanoparticles exhibit 
an absence of hollow morphology. This clearly suggests that the precise nanoscale 
etching of MONs in our system is only possible when two key conditions are fulfilled: 
the presence of acetate ions and a mildly acidic pH environment. Indeed, the role of 
acetate anions to produce hollow MONs via the Kirkendall effect has been 
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demonstrated previously.[5] However, it appears that the provision of an acidic 
medium in the system has altered the nature of the etching mechanism. In this regard, 
it is postulated that the acetate ions present in our choice of etchant solution are able 
to adsorb strongly onto the surface of MONs and stabilize the exterior layer from 
dissolution. As a result, the H+ ions (acidic pH) will attack along the randomly 
distributed regions of high defect densities in the particle interior to form small 
cavities. During the course of the etching process, these interior cavities will gradually 
enlarge and coalesce, thereby causing a preferential removal of the MnO core to form 
the hollow nanostructure. 
 
Lastly, when regular aliquots of the solution are tested for their Mn concentration 
during the etching process, it is observed that there is a gradual decline in the Mn 
content (Figure 6.5c). This shows that after the core dissolution, the interior Mn2+ ions 
can readily diffuse through the nanoreactor walls to prevent a toxic accumulation of 
Mn2+ ions within the framework, thus not impeding their use as T1 MRI contrast 
agents for biomedical applications. 
 
6.3.4 Assessment of Biocompatibility 
 
Cytotoxicity of hollow MONs with multiple 16-nm cores was evaluated using the 
Alamar blue assay. Figure 6.6 shows that more than 80% of the HeLa cells remained 
viable after 12-hour incubation at a high nanoparticle concentration of 480 μg/mL. 
Based on ICP-AES, this corresponds to 0.448 mM of Mn, which exceeds the dose 
concentration of 0.40 mM used for the in vivo MR imaging of mouse in our study 
(Figure 6.3b). Hence, it indicates that the nanoparticles are relatively non-cytotoxic at 
Chapter 6: Nanoscale Etching of Manganese Oxide Nanoparticles  
 123 
the concentration range required for sufficient MRI contrast sensitivity. The excellent 
biocompatibility of hollow MONs is due to the two constituent materials that form the 
nanoreactor backbone: Firstly, the nanostructured silica is an inert and biocompatible 
material that is commonly used for drug delivery and nanomedicine applications.[23,24] 
Secondly, F127, being a PEO-based block copolymer, has been approved by FDA for 
parenteral administration and is widely used for pharmaceutical applications.[25,26] 
 
Figure 6.6 Viability of HeLa cells cultured in the presence of hollow MONs for 12 hours. 
 
Based on reports available in the literature on biodistribution studies with 
nanoparticles of similar size (50 – 100 nm) and composition (silica and PEO/PEG 
conjugates), the majority of such nanoparticles tend to accumulate in the mice liver 
and spleen due to the reticuloendothelial system that exists in these organs.[27,28] There 
was evidence of renal excretion as the nanostructured silica would biodegrade to form 
silicic acid or oligomeric silica species and be eliminated by the urinary system. 
Nonetheless, most of the nanoparticles were predominantly eliminated via the faecal 
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hollow MONs as hepatobiliary-specific MR contrast agents since they would be 
readily taken up by functioning hepatocytes and excreted in the bile. Among the 
potential applications of these nanoparticles, they include the improvement of lesion 





In this chapter of the project, we have successfully developed the novel use of the 
hybrid silica nanocapsules as nanoreactors to encapsulate MONs with well-defined 
hollow nanostructures. Due to the incorporation of hydrophilic PEO-based polymer 
channels into the stable silica framework, it allows for the etching chemistry to be 
conducted in a confined volume under controlled conditions and selective 
permeability. More importantly, the silica nanoreactors are able to maintain their 
structural integrity and aqueous dispersity under the benign conditions of etchant 
treatment. 
 
The versatility of this new synthesis protocol has been demonstrated by the successful 
formation of hollow MONs with different nanocomposite architectures. Herein, the 
correlation of various factors, such as the MON morphology (solid or hollow 
nanoparticles) and number of MONs (single or multiple) are analysed and discussed. 
Although different nanostructural parameters can lead to positive contrast 
enhancement, there are distinct differences with regards to the magnitude. In 
particular, we have observed a significant increase in the r1 relaxivity if an optimal 
number of MONs is encapsulated within the framework. Hence, it represents an 
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alternative approach to design high-performance MON-based MRI contrast agents.  
Finally, we have proposed an alternative etching mechanism to highlight the essential 
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Chapter 7  
pH-ACTIVATABLE MANGANESE OXIDE-BASED 




Interventional oncology, which employs minimally invasive, image-guided 
technology to target solid tumours directly, has recently emerged as the fourth pillar of 
cancer therapy, alongside the classical treatment options of surgery, chemotherapy and 
radiotherapy.[1] It is in this context that the adoption of dual-modality imaging probes 
with fluorescence and MR imaging capabilities can offer significant utility to the 
diagnostic and treatment process. For example, MR imaging can first be performed 
for preoperative cancer staging and surgical planning, followed by an intraoperative 
tumour-specific fluorescence imaging to guide the scalpel and improve the 
management of cancers.[2] 
 
The feasibility of this approach to increase the precision of surgical resection was 
successfully demonstrated by Kircher and co-workers, who employed bimodal (near-
infrared fluorescent and magnetic) nanoparticles to accentuate the delineation of brain 
tumours.[3] Hence, there is a growing interest to develop dual MR/fluorescence 
imaging nanoprobes. Popular combinations typically consist of SPIONs or gadolinium 
chelates for the MRI contrast agents, while organic fluorophores, quantum dots or 
upconversion lanthanide compounds are employed for the fluorescence imaging 
component.[4] 
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In order to improve the sensitivity and specificity of cancer detection, recent 
developments also emphasized the advantages of pH-activatable imaging modality for 
cancer diagnostics.[5-7] The rationale behind such a feature is for the imaging 
nanoprobe to remain silent during blood circulation and achieve selective activation 
only upon sequestration into the acidic milieu of tumours or the lyosomal 
compartment of cancer cells, thus increasing the target-to-background signal ratio in 
cancer cell imaging. However, most of the previously reported studies are based solely 
on pH-responsive fluorescence for optical imaging as it still remains a challenge to 
incorporate the MR imaging modality into the design of pH-responsive nanoprobes.  
 
In this regard, there is an incompatibility of conventional MRI contrast agents under 
acidic conditions. SPIONs tend to dissolve at low pH to result in a loss of their 
magnetic properties and thus the corresponding T2 contrast effect. In addition, the 
chelation chemistry of GBCAs are susceptible to alteration under low pH, thereby 
causing ligand protonation and the release of toxic Gd3+ ions.[8] However, MONs are 
attractive as a new class of MRI contrast agents due to their capacity to exert higher 
T1 contrast at low pH conditions. Bennewitz et al. proposed that this could likely be 
due to the acidic dissolution of the MONs to release Mn2+ ions,[9] which have a 
substantially higher r1 relativity as compared to the metal oxide counterparts.[10] 
Therefore, this would facilitate the dynamic visualization of tumours by way of their 
slightly acidic pH. To the best of our knowledge, while there has been ongoing work 
on the use of redoxable MnO2 nanosheets that respond to intracellular GSH for 
fluorescence activation,[11-13] the design of a pH-responsive MnO-based 
fluorescence/MR dual imaging nanoprobe is unprecedented. 
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Therefore, in the present study, we report the successful development of a novel pH-
activatable dual-modality nanoprobe, which is primarily composed of the co-
encapsulation of MONs and C545T inside PEOSNs (hereafter denoted as MCNCs). 
Due to the close spatial proximity in the micelle core, it is envisaged that the MONs 
would serve to quench the fluorophores of C545T effectively under normal 
physiological conditions. However, fluorescence activation is triggered upon the 
dissolution of MONs in the acidic lysosomal compartment of cancer cells. 
 
The nanoprobes are also conjugated with FA for active targeting of FR-positive cancer 
cells. Meanwhile, the utilization of the PEO-silica nanoshell would confer excellent 
biocompatibility and high colloidal stability to the hydrophobic payload, as well as to 
prevent the premature dissolution of the MONs until the nanoprobe is delivered 
intracellularly into the cancer cells. This would lead to higher imaging sensitivity and 
specificity for the targeting cancer cells, hence demonstrating promising utility for 
tumour visualization and interventional oncology. 
 
7.2 Experimental Details 
7.2.1 Chemicals and reagents 
 
Pluronic® F127 (PEO106PPO70PEO106), 1-hexadecene, dimethylsulfoxide (DMSO), N-
hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), 
TMOS, THF, potassium hydrogenphosphate trihydrate (K2HPO4.3H2O), sodium 
bicarbonate (NaHCO3), magnesium chloride hexahydrate (MgCl2.6H2O), 1M HCl, 
calcium chloride (CaCl2), sodium sulfate (Na2SO4), D-(+)-glucose solution, sodium 
acetate trihydrate (CH3COONa.3H2O) and MTT reagent were purchased from Sigma 
Chapter 7: pH-activatable MnO-based Nanoprobe  
 131 
Aldrich. Tris(hydroxymethyl)aminomethane (NH2C(CH2OH)3), potassium chloride 
(KCl) and sodium chloride (NaCl) were purchased from Merck Millipore. Glacial 
acetic acid was purchased from J.T. Baker. C545T was obtained from TCI America. 
10× PBS solution was obtained from 1st Base. FBS was purchased from Hyclone. The 
HeLa cells, as well as the cell culture media (DMEM), supplements and trypsinization 
solution were obtained from ATCC. The HaCaT cells were kindly provided by Dr. 
Aaron Tan. Dicarboxylic acid modified F127 (F127-COOH) and aminated folic acid 
(NH2-PEO-FA) were synthesized according to a previous report.[26] 
 
7.2.2 Synthesis of MONs 
 
In accordance to previously published reports,[14,15] the preparation of manganese 
oleate precursor and MONs have been described in Chapter 4. Briefly, MONs were 
synthesized by the thermal decomposition of manganese oleate precursor dissolved in 
1-hexadecene at elevated temperatures. 
 
7.2.3 Synthesis of FA-conjugated MCNCs 
 
A stock solution of C545T in THF was first prepared by dissolving the dye in THF to 
a concentration of 1mg/mL. In a typical synthesis process, the C545T stock solution 
(25-100 μL) was mixed with 300 μL of the MON stock solution and 500 μL of THF. 
10 mg of F127-COOH and 30 mg of F127 were then dissolved in the mixture solution 
and stirred at room temperature for 1 hour prior to the addition of 50 μL of TMOS. 
Next, the reaction mixture was injected slowly into 10 g of deionised water while 
stirring at 1000 rpm. The solution was subsequently stirred at 500 rpm for four days to 
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ensure the complete hydrolysis and condensation of TMOS. The resulting aqueous 
dispersion was dialyzed against deionised water for 24 hours by using MWCO 8000 
dialysis membrane to remove any unreacted silica precursors. Next, the nanoparticle 
solution was centrifuged at 6000 rpm for 10 minutes and the isolated pellet is re-
dispersed in 10 g of deionized water to form an aqueous solution of carboxylic acid 
functionalized MCNCs. Next, 13.5 mg of EDC and 8.1 mg of NHS were dissolved 
into the aqueous solution of carboxylic acid functionalized MCNCs and stirred for 30 
minutes, followed by the slow injection of NH2-PEO-FA solution into the nanoparticle 
solution. The NH2-PEO-FA solution was prepared by dissolving 4.5 mg of NH2-PEO-
FA in 50 μL of DMSO and 700 μL of deionized water. The reaction mixture was 
allowed to continue for another 48 hours at room temperature. The final solution was 
dialyzed against deionised water for 24 hours by using the MWCO 8000 dialysis 
membrane. 
 
7.2.4 Synthesis of FA-conjugated CNCs 
 
A similar protocol was used to prepare FA-conjugated CNCs. Briefly, 10 mg of F127-
COOH and 30 mg of F127 were dissolved in 500 μL of THF. 50 μL of the C545T 
stock solution was then added to the mixture solution and stirred at room temperature 
for 1 hour prior to the addition of 50 μL of TMOS. Next, the reaction mixture was 
processed according to the procedures described above, except that it was not 
subjected to centrifugation and redispersion after the first round of water dialysis. 
 
  




TEM (JEM-2010F, 200 kV) was employed to study the morphology of the 
nanoparticles. DLS (Malvern Zetasizer Nanoseries) was performed using a HeNe 
laser (633 nm) to measure the size and size distribution of the nanoparticles. FT-IR 
(Varian 3100 Excalibur) and energy-dispersive X-ray spectroscopy (EDX, JEM-
2010F, 200 kV) were used to study the elemental composition of MCNCs. XRD 
(Bruker AXS D8 Advance) was conducted under Cu Kα radiation (λ = 1.5406 Å) at a 
scanning rate of 2θ = 2°/min over a range of 2θ = 15–50° to identify the crystalline 
phase in MCNCs. The optical properties of the nanoparticles were studied by 
photoluminescence spectroscopy (Elmer LS 55 spectrophotometer) while the UV-vis 
absorption spectra were recorded with the Shimadzu UV-3101 PC spectrophotometer. 
The Mn concentration of MCNCs was determined by ICP-AES. 
 
7.2.6 Biostability study 
 
The preparation procedure for simulated body fluid (SBF) was described in previously 
published reports.[27,28] Briefly, the following reagents were dissolved in deionized 
water and the solution was filled up to 1.0 L: NaCl (7.996 g), NaHCO3 (0.350 g), KCl 
(0.224 g), K2HPO4.3H2O (0.228g), MgCl2.6H2O (0.305 g), CaCl2 (0.278 g), Na2SO4 
(0.071 g), 1 M HCl (40 mL) and NH2C(CH2OH)3 (6.057 g). The ionic composition of 
the resulting solution would be similar to that of human blood plasma. Meanwhile, 
1×PBS was prepared by diluting the 10×PBS with deionized water. The PBS solution 
was then supplemented with 10% (v/v) FBS. The pH of both solutions was regulated 
at 7.4. Next, 300 μL of the suspended MCNCs sample was dispersed in a small aliquot 
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of either solutions (3 mL). The mixture solution was stirred at 500 rpm for 5 minutes, 
then transferred to a cuvette for DLS analysis. The change in the hydrodynamic size 
of MCNCs was monitored as function of time at 37°C. 
 
7.2.7 Photoluminescence study 
 
SBF and PBS were formulated as above. The acetate buffer solution was prepared by 
mixing 0.1M acetic acid (350 mL) to 0.1M sodium acetate (650 mL). Saline solution 
was prepared by dissolving 8.5g of NaCl to 1 L of deionized water. The glucose 
solution was prepared at a concentration of 6 mM. The final pH of the respective 
solutions was achieved by adding HCl or NaOH. To characterize the fluorescence 
response of MCNCs in the various biological solutions, 10 mL of the MCNCs sample 
was transferred into a MWCO 8000 dialysis membrane and dialyzed for 48 hours at 
room temperature. At selected time intervals, an aliquot of the sample solution (1 mL) 
was retrieved from the dialysis membrane to record the photoluminescence spectrum, 
then reinserted back into the dialysis tube for further immersion. 
 
7.2.8 Cytotoxicity assay 
 
The cell viability of HeLa cells was assessed through MTT assay. Briefly, HeLa cells 
were seeded in a 24-well plate at a density of 5 × 104 cells per well in the presence of 
a growth medium. The culture medium contains completed DMEM with 10% FBS, 
penicillin (100 U/mL) and streptomycin (100 μg/mL). Next, MCNCs of different 
concentrations were added to the cells, which were incubated further for 12 or 24 
hours at 37°C under 5% CO2. Thereafter, MTT reagent was added to each well, and 
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the plate was incubated for 4 hours at 37°C. MTT assay was carried out according to 
the manufacturer’s instructions. All samples were assayed in triplicate. 
 
7.2.9 Cell culture and labelling 
 
Two different mammalian cell lines, namely HeLa and HaCaT cell were chosen to 
study the effect of folate conjugation of MCNCs on cellular internalization. HeLa and 
HaCaT cells were separately seeded in 24-well plates in completed DMEM with 10% 
FBS, penicillin (100 U/mL) and streptomycin (100 μg/mL). Both cell lines were 
incubated with MCNCs (300 μg/mL) for 12 hours. Following the exposure, the cell 
lines were washed using cell culture media and subsequently imaged at ambient 
temperature by conventional light and fluorescence microscopy, respectively. In order 
to investigate the fluorescence activation of MCNCs upon cellular uptake, HeLa cells 
were maintained under similar cell culture conditions as above. After cell seeding onto 
the 24-well plate, the HeLa cells were incubated with MCNCs (300 μg/mL) for 3 
hours. All the wells were then washed with PBS for two times and replaced with fresh 
DMEM media. Thereafter, HeLa cells in the different columns of wells were cultured 
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7.2.10 MRI properties of MCNCs 
 
To measure the pH-sensitive MRI properties of MCNCs, the nanoparticles were 
suspended in deionized water (pH 7) and acetate buffer solution (pH 5) for 48 hours, 
respectively. With both solutions, the T1-mapping was performed on horizontal bore 
9.4 T Agilent scanner with 35 mm RF coil, using a multi-slice Look-Locker sequence 
on VnmrJ software (TR=3.1 ms; TE=1.1 ms; field of view 30x30 mm; data matrix 
128x128; three 1 mm slices; 1 average; 100 inversions from 0.033 to 7.45 ms; scan 
time approx. 4 min). The longitudinal (r1) relaxivities were also obtained from the 
slope of 1/T1 versus molar Mn concentration plots. Data were analysed using 
MATLAB in-house scripts. 
 
7.2.11 In vitro MRI 
 
The HeLa cells were first seeded in 6-well plate at a density of 2 × 106 cells per well, 
then incubated with MCNCs of varying concentrations for 24 hours at 37°C under 5% 
CO2. After incubation, the cell media was aspirated; HeLa cells were washed with 
PBS for 2 times, then trypsinized and collected into 2 mL Eppendoff tubes. For each 
tube, the content was centrifuged at 5000×g for 5 minutes and the resulting cell pellet 
was redispersed in 600 μL of PBS prior to further cell fixation. For preparation of cell 
phantoms, the suspension of fixed HeLa cells in 200 μL of PBS was transferred into 
0.4 mL microcentrifuge tubes and mixed thoroughly with 200 μL of 2% agarose. A 
turbo spin echo sequence was optimized to generate T1-weighted images of the in 
vitro phantoms, the relevant acquisition parameters being TR/TE: 955/8.9 ms, number 
of averages (NA: 16). 
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7.3 Results and discussion 
7.3.1 Preparation and characterization of MCNCs 
 
Scheme 7.1 Schematic illustration of the synthesis and working principles of MCNCs. 
 
For this class of pH-activatable dual modality nanoprobe, the evolution of its 
hierarchical nanostructure is illustrated in Scheme 7.1. Briefly, monodisperse MONs 
were pre-synthesized by the thermal decomposition of manganese oleate precursor in 
1-hexadecene solvent.[14,15] Next, a mixed payload of C545T and MONs was 
encapsulated into a carboxylic acid functionalized silica nanoshell by an interfacial 
templating scheme.[16] Finally, by using NHS and EDC coupling agents, aminated FA 
was conjugated to the carboxylic acid groups for active targeting of cancer cells. 
 
The successful FA conjugation onto MCNCs was verified by UV-vis analysis (Figure 
7.1a), which indicates a broad absorption band in the region of ~300 nm. This is 
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ascribed to the π to π* transition of the pterin ring of the FA molecule.[17] The results 
are also supported by the negative zeta potential of MCNCs (-14.7 mV), which is 
presumably due to the carboxyl groups of FA conjugated to the particle surface.[18] In 
addition, the smaller doublet peak at 425 and 452 nm is due to the mixed payloads of 
MONs and C545T. This was confirmed by absence of the corresponding peak in the 
absorption spectrum of empty silica nanocapsules that were similarly prepared by the 
interfacial templating scheme (Figure 7.1b). 
 
Figure 7.1 UV-vis absorption spectra of: (a) MCNCs; and (b) empty silica nanocapsules with different 
organic constituents in the silica nanoshell layer. 
 
Formation of the small doublet peak could be accounted for by the high scattering 
background of MONs (Figure 7.2a), which causes an over-estimation of the 
absorption intensity at the shorter wavelength region.[19] As a result, the single 
absorbance band of C545T (Figure 7.2b) becomes distorted, thus giving rise to the 
characteristic doublet peak of MCNCs. For comparative purposes, fluorescent silica 
nanocapsules with only C545T as the payload were also prepared (hereafter denoted 
as CNCs). 
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Figure 7.2 (a) UV-vis absorption spectra of silica-coated MONs and Mn2+ ions in aqueous solution. 
The absorption band intensities of Mn2+ ions are significantly lower than those of silica-coated MONs. 
(b) Normalized absorption spectra of C545T in THF solvent (solid lines) and the C545T-encapsulated 
fluorescent silica nanocapsules (CNCs, dashed lines). The absorption peak of C545T exhibits a blue-
shift to the shorter wavelength region upon encapsulation. 
 
TEM study (Figure 7.3a) reveals that the as-synthesized MCNCs are generally < 50 
nm in sizes, which is an ideal dimension for prolonging their blood circulation time, 
allowing extravasation into tumour tissues through fenestrations of the angiogenic 
vasculature and facilitating cellular uptake. The MCNCs also exhibit a nanocomposite 
architecture that is composed of a darker manganese oxide core and a brighter silica 
shell. Such an elemental distribution of the core-shell nanostructure was verified by 
the EDX analysis of MCNCs (Figure 7.3d), which indicates clear traces of Mn, Si and 
O while the strong Cu signal is derived from the copper TEM grid. In contrast, the 
CNCs exhibited a donut shape with slight contrast between the darker silica shell and 
the brighter polymeric core containing C545T (Figure 7.3b). 
 
From Scheme 7.1, it is also evident that F127 is an essential component of MCNCs. 
Besides serving as a template to direct the silica nanoshell formation, the retained 
PEO block of F127 would provide a surface corona of PEO chains, thus improving 
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the aqueous dispersibility and antifouling properties of MCNCs, as well as to impart 
further functionality to which the FA ligands can be attached. Their presence is be 
verified by the XRD pattern of MCNCs (Figure 7.3c), which shows the typical 
signature peaks of crystalline PEO in F127.[20] 
 
Figure 7.3 TEM images of the as-synthesized (a) MCNCs; and (b) CNCs. (c) XRD patterns of MCNCs 
(top) and CNCs (bottom). The full blue square indicates the diffraction peaks due to the crystalline 
PEO of F127. The # sign indicates the diffraction peaks due to the crystalline MnO phase of MONs. (d) 
EDX spectrum of MCNCs. 
 
7.3.2 pH-responsive behaviour of MCNCs 
 
As a proof-of-concept to demonstrate the pH-responsive behaviour of MCNCs, the 
nanoparticles were dialyzed in an acetate buffer solution at pH 5.0. The fluorescence 
data acquired showed that there was a significant, albeit gradual increase in the 
fluorescence intensity of the MCNCs solution over the course of 48 hours dialysis 
(Figure 7.4a). These observations confirm that the gradual acidic dissolution of MONs 
has brought about a fluorescence recovery of MCNCs. This is because the evolved 
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free Mn2+ ions, which have a spin sextet due to their d5 electron configuration, are 
spin-forbidden for all of its transitions from the ground state since they involve a 
change in the number of unpaired electrons.[21,22] As a result, the Mn2+ ions have very 
low absorption band intensities and are unable to quench the fluorescence of C545T as 
effectively as MONs (Figure 7.2a). 
 
When compared against the emission spectrum of C545T in THF (Figure 7.4b), the 
fluorescence profile of MCNCs at the 48-hour time point is also considerably blue-
shifted and broadened, with an emission shoulder between 440 to 480 nm. This 
spectral profile suggests the probable emergence of a monomer-aggregate coupled 
fluorescence system during the course of acidic immersion. The blue-shifted 
secondary emission shoulder is attributed to the H-aggregation of C545T.[23] 
 
Figure 7.4 (a) Fluorescence emission spectra of MCNCs in acetate buffer solution (pH 5) measured as 
a function of immersion time. (b) Photoluminescence spectra of C545T in THF solvent. A strong 
emission peak at ~520 nm was exhibited; this suggested an absence of the H-aggregation of C545T 
when dissolved in THF. 
 
MCNCs of different MON:C545T ratio were prepared by adding 300 μL of MONs to 
different volumes of C545T (25 μL, 50 μL or 100 μL) prior to their encapsulation into 
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the hybrid silica shell. Herein, the dominance of F127 peaks was always observed in 
the FT-IR spectra of the synthesized MCNCs, regardless of the MON:C545T ratio 
(Figure 7.5a). For these MCNCs (denoted as low, medium and high, in the order of 
increasing loading amount of C545T), the degree of fluorescence recovery was also 
investigated by measuring their fluorescence intensity. The fluorescence enhancement 
factor (FEF) is determined by the ratio of the absolute fluorescence intensity value at 
492 nm during (F) and prior to (F0) immersion in the acetate buffer solution. 
 
Figure 7.5 (a) FT-IR spectra of MCNCs with the increasing loading concentration of C545T (bottom to 
top). (b) Fluorescence enhancement factor F/F0 of MCNCs with different loading concentrations of 
C545T as a function of immersion time. 
 
It was initially anticipated that a higher loading concentration of C545T would cause a 
stronger fluorescence emission upon nanoprobe activation. However, contrary to our 
expectation, Figure 7.5b indicates that the optimal fluorescence enhancement (FEF = 
58.0) was achieved when a moderate amount of C545T is used. One explanation is 
that at the exceedingly high loading concentration of the organic dye, the C545T H-
aggregates would grow from dimers to higher order aggregates, thereby causing the 
quantum efficiencies to decrease accordingly.[23] 
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Ideally, the fluorescence of MCNCs should only be activated in response to acidic 
conditions. To this extent, we have tested for possible fluorescence response of 
MCNCs at different pH values and electrolytes. In a similar manner as discussed 
before, the FEF is determined after 48-hour dialysis in the respective solution media 
and compared against the acidic acetate buffer as a reference. Table 7.1 demonstrates 
that notable fluorescence activation could only be achieved under acidic conditions 
and was progressively more apparent at lower pH. This confirms the high specificity 
of MCNCs for pH-activatable imaging and would ensure that the nanoprobes 
remained largely quenched prior to their uptake by the targeted cells. It is noteworthy 
that even for the non-acidic solution media, there was still a very small degree of 
fluorescence increase (FEF = 2–3), which could not be visualized under the UV lamp. 
This imperceptible fluorescence is due to the slight release of C545T from the core 
interior into the surrounding aqueous media over time. 
 
Table 7.1 Fluorescence response of MCNCs at different electrolytes and pH. 
Solution medium pH FEFa) Normalized 
Intensity [%] 
Acetate buffer 5.0 58.0 100 
PBS solution 6.2 10.3 17.7 
Deionized water 7.0b) 2.39 4.1 
0.85% saline solution 7.0b) 2.23 3.8 
6 mM glucose solution 7.0b) 2.33 4.0 
PBS solution 7.4 2.40 4.1 
Simulated body fluid 7.4 1.92 3.3 
PBS solution 8.0 2.67 4.6 
a)Fluorescence enhancement factor; 
b)Non-buffered solution; solution medium is changed every 4 hours to maintain a constant pH 
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Finally, the relevance of the pH-responsive behaviour of MCNCs to MR T1 imaging 
was examined by obtaining the T1 maps of MCNCs after 48-hours incubation at either 
pH 5 or 7. From Figure 7.6a, it is evident that the MCNCs of different nanoparticle 
concentrations exhibited a significantly stronger MRI signal enhancement at pH 5 
than that at pH 7. Based on the corresponding r1 values, this translates to more than a 
7-fold increase in T1 contrast under the mild acidic conditions (Figure 7.6b). On the 
other hand, the CNCs with C545T payload exhibited negligible signal enhancement 
even at pH 5 when compared to the control sample of water. 
 
Figure 7.6 (a) False-colour heat map showing the T1 values (ms) of CNCs (pH 5), water (pH 7) and 
MCNCs at different concentrations (pH 5 and 7). (b) Plots of 1/T1 versus Mn concentration for MCNCs 
at pH 5 (red) and pH 7 (blue), respectively. r1 and R
2 represent gradient of the line and the coefficient 
of determination, respectively, at the different pH conditions. (This work is done in collaboration with 
UCL Centre for Advanced Biomedical Imaging.) 
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On the basis of these results, it is concluded that C545T is not responsible for the pH-
responsive MRI behaviour of MCNCs. Instead, it is caused by the acidic dissolution 
of encapsulated MONs to release Mn2+ ions. More importantly, we have successfully 
validated the design tenets of MCNCs as a pH-activatable dual-modality nanoprobe. 
 
7.3.3 Cytotoxicity and antifouling study of MCNCs 
 
Biocompatibility and biostability are pivotal considerations for the potential 
application of MCNCs in cancer cell imaging and tumour visualization. In this regard, 
the cytotoxicity of MCNCs was assessed with HeLa cells using the MTT cell viability 
assay (Figure 7.7a). The excellent biocompatibility of MCNCs was confirmed where 
more than 90% of the HeLa cells survived despite the co-incubation with 300 μg mL-1 
of MCNCs for 24 hours. 
 
In addition, to verify the biostability of MCNCs under the physiological conditions, 
the nanoparticles were immersed in different physiological solutions at 37 °C, namely 
(a) SBF, and (b) PBS solution with 10% FBS. From a macroscopic perspective, the 
MCNCs were well-dispersed in both solutions, without any signs of aggregation over 
the test period of 24 hours. This was also evidenced from DLS analysis (Figure 7.7b), 
which indicated an absence of significant changes in the hydrodynamic size of 
MCNCs upon incubation for 24 hours. Hence, besides displaying excellent colloidal 
stability in highly salted buffers, the MCNCs also exhibited antifouling behaviour to 
prevent non-specific protein adsorption. This is be useful to prevent the susceptibility 
to particle aggregation and avoid recognition by the reticuloendothelial system in the 
human body. 
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Figure 7.7 (a) MTT assay of HeLa cells. Cells were incubated with various concentrations of 
MCNCs for 12 and 24 hours, respectively. (b) Change in hydrodynamic size of MCNCs measured 
as a function of time upon incubation in SBF and PBS containing 10% (v/v) FBS at 37 °C, 
respectively. 
 
7.3.4 Cell culture and cellular imaging 
 
A comparative in vitro study was conducted using human dermal (HaCaT) and 
cervical cancer (HeLa) cell lines to investigate how cells of diverse origin would react 
to MCNCs. Optical micrographs and fluorescence microscopy images of each cell 
lines after a 12-hour exposure to MCNCs are illustrated in Figure 7.8 Interestingly, the 
HaCaT cells exhibited a higher proliferative capacity to form colonies on exposure to 
the nanoparticles. There was also a considerable degree of green fluorescence in the 
HeLa cells, while the HaCaT cells exhibited minimal fluorescence brightness. This is 
attributed to the over-expression of FR on HeLa cells (FR+ve) as compared to HaCaT 
cells (FR-ve).[24] Thus, the folate conjugation on MCNCs will favour a higher 
internalization efficiency for the HeLa cells. 
 
Fluorescence microscopy was also used to investigate the process of fluorescence 
restoration upon cellular uptake. Herein, the HeLa cells were first incubated with 
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MCNCs for 3 hours, followed by an exchange to fresh media, then fixed at the 12- or 
24-hour time points prior to fluorescence imaging. Exposure of the HeLa cells to 
CNCs with C545T payload only was carried out as a positive control. From Figure 
7.9, the HeLa cells labelled with MCNCs exhibited a gradual enhancement in 
fluorescence. In contrast, there was no indication of a time-dependent increase in 




Figure 7.8 Optical micrographs of (a) HaCaT cells; and (b) HeLa cells after 12-hour MCNCs exposure 
at 300 μg/mL. Fluorescence microscopy images of (c) HaCaT cells, and (d) HeLa cells under similar 
cell culture conditions. (This work is done in collaboration with UCL Centre for Nanotechnology and 
Regenerative Medicine.) 
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Figure 7.9 Fluorescence microscopy images of HeLa cells labelled by (a) MCNCs; and (b) CNCs 
of 3-hour incubation as a function of time. The exchange to fresh media after 3-hour incubation 
prevents further cellular uptake of the nanoparticles. (This work is done in collaboration with UCL 
Centre for Nanotechnology and Regenerative Medicine.) 
 
From these findings, it strongly supports the effectiveness of MONs to quench the 
fluorophores of C545T and cause a delayed activation of fluorescence upon receptor-
mediated endocytosis into the cell compartments. Although further work is needed to 
accurately determine the subcellular distribution of MCNCs in the cells, published 
literature suggested that nanoparticles derivatized with multiple folates are typically 
trafficked to the acidic endosomes.[25] Therefore, it is postulated that the MCNCs 
could similarly follow the endo-lysosomal internalization pathway. The subsequent 
endosomal escape of nanoparticles is unlikely due to the non-cationic character of 
MCNCs, which could otherwise cause the swelling and rupture of endosomes. As a 
result, the lysosomal accumulation of MCNCs would trigger the fluorescence 
restoration of MCNCs in the HeLa cells. 
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7.3.5 In vitro MRI study 
 
To investigate the performance of MCNCs to concurrently function as a MRI contrast 
agent for cancer cell labelling, HeLa cells were incubated with MCNCs of different 
nanoparticle concentrations for 24 hours. Figure 7.10a shows the T1-weighted MR 
image of the HeLa cells after MCNCs exposure; it depicts a concentration-dependent 
MRI signal enhancement as the positive T1 contrast of the tubes (containing the HeLa 
cells) becomes brighter with the increasing concentration of nanoparticles. This can 
also be verified by the inversion-recovery pulse sequence (Figure 7.10b), which 
illustrates that the higher MCNC concentrations would lead to a faster longitudinal 
recovery, thus a more efficient shortening of the T1 relaxation time. 
 
Figure 7.10 (a) T1-weighted MR images; and (b) the longitudinal recovery following an inversion pulse 
for HeLa cells incubated with different concentrations of MCNCs. (This work is done in collaboration 
with SBIC.) 
 
Moreover, these results also suggest the low cytotoxicity of MCNCs for the range of 
nanoparticle concentration studied. Hence, there could be a higher cellular uptake of 
MCNCs by the HeLa cells to generate a stronger MRI contrast without significant 
effect on cellular viability. 




This chapter has described the development of a new pH-activatable MnO-based 
nanoprobe for bimodal imaging of cancer cells. The pH-responsive behaviour of 
MCNCs was successfully validated using an acetate buffer solution (pH 5) to trigger 
the fluorescence recovery and T1 MRI contrast enhancement under acidic conditions. 
Moreover, the nanoprobes were also shown to exhibit excellent biocompatibility and 
biostability, thus they can offer significant utility for cancer diagnostic applications. 
 
At the cellular level, the MCNCs were observed to be preferentially internalized by 
HeLa cells (FR+ve) due to the surface conjugation of FA. Besides, these nanoparticles 
could allow for the detection of cancer cells with both MR and fluorescence imaging 
techniques while the delayed fluorescence restoration of MCNCs upon cellular uptake 
would greatly increase the target-to-background signal ratio for higher imaging 
sensitivity. Therefore, MCNCs would have tremendous diagnostic potential for the 




[1] R. Hickey, M. Vouche, D. Y. Sze, E. Hohlastos, J. Collins, T. Schirmang, K. 
Memon, R. K. Ryu, K. Sato, R. Chen, R. Gupta, S. Resnick, J. Carr, H. B. 
Chrisman, A. A. Nemcek Jr., R. L. Vogelzang, R. J. Lewandowski, R. Salem. J. 
Vasc. Interv. Radiol. 2013, 24, 1157–1164. 
[2] M. Niedre, V. Ntziachristos. Proc. IEEE 2008, 96, 382–396. 
[3] M. F. Kircher, U. Mahmood, R. S. King, R. Weissleder, L. Josephson. Cancer 
Chapter 7: pH-activatable MnO-based Nanoprobe  
 151 
Res. 2003, 63, 8122–8125. 
[4] J. Kim, Y. Piao, T. Hyeon. Chem. Soc. Rev. 2009, 38, 372–390. 
[5] D. Ling, M. J. Hackett, T. Hyeon. Nat. Mater. 2014, 13, 122–124. 
[6] Y. Wang, K. Zhou, G. Huang, C. Hensley, X. Huang, X. Ma, T. Zhao, B. D. 
Sumer, R. J. DeBerardinis, J. Gao. Nat. Mater. 2014, 13, 204–212. 
[7] L. Wang, C. Li. J. Mater. Chem. 2011, 21, 15862–15871. 
[8] Z. Zhou, Z.-R. Lu. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2013, 5, 
1–18. 
[9] M. F. Bennewitz, T. L. Lobo, M. K. Nkansah, G. Ulas, G. W. Brudvig, E. M. 
Shapiro. ACS Nano 2011, 5, 3438–3446. 
[10] Y.-C. Lee, D.-Y. Chen, S. J. Dodd, N. Bouraoud, A. P. Koretsky, K. M. 
Krishnan. Biomaterials 2012, 33, 3560–3567. 
[11] R. Deng, X. Xie, M. Vendrell, Y.-T. Chang, X. Liu. J. Am. Chem. Soc. 2011, 
133, 20168–20171. 
[12] Z. Zhao, H. Fan, G. Zhou, H. Bai, H. Liang, R. Wang, X. Zhang, W. Tan. J. Am. 
Chem. Soc. 2014, 136, 11220–11223. 
[13] P. Zhao, Y. Zhu, X. Yang, J. Shen, X. Jiang, J. Zong, C. Li. Dalton Trans. 2014, 
43, 451–457. 
[14] B. Y. W. Hsu, M. Wang, Y. Zhang, V. Vijayaragavan, S. Y. Wong, A. Y. C. 
Chang, K. K. Bhakoo, X. Li, J. Wang. Nanoscale 2014, 6, 293–299. 
[15] T. D. Schladt, T. Graf, W. Tremel. Chem. Mater. 2009, 21, 3183–3190. 
[16] H. Tan, N. S. Liu, B. He, S. Y. Wong, Z. K. Chen, X. Li, J. Wang. Chem. 
Commun. 2009, 41, 6240–6242. 
[17] P. Huang, L. Bao,C. Zhang, J. Lin, T. Luo, D. Yang, M. He, Z. Li, G. Gao, B. 
Gao, S. Fu, D. Cui. Biomaterials 2011, 32, 9796–9809. 
Chapter 7: pH-activatable MnO-based Nanoprobe  
 152 
[18] R. N. Mitra, M. Doshi, X. Zhang, J. C. Tyus, N. Bengtsson, S. Fletcher, B. D. G. 
Page, J. Turkson, A. J. Gesquiere, P. T. Gunning, G. A. Walter, S. Santra. 
Biomaterials 2012, 33, 1500–1508. 
[19] C. Würth, M. Grabolle, J. Pauli, M. Spieles, U. Resch-Genger. Nat. Protoc. 
2013, 8, 1535–1550. 
[20] P. Innocenzi, L. Malfatti, M. Piccinini, A. Marcelli. J. Phys. Chem. A 2010, 114, 
304–308. 
[21] Y. Tanabe, S. Sugano. J. Phys. Soc. Jpn. 1954, 9, 766–779. 
[22] C. K. Jørgensen. Acta Chem. Scand. 1954, 8, 1502–1512. 
[23] D. Mao, X. Liu, Q. Qiao, W. Yin, M. Zhao, J. C. Cole, J. Cui, Z. Xu. Analyst 
2015, 140, 1008–1013. 
[24] S. Mohapatra, S. R. Rout, R. Narayan, T. K. Maiti. Dalton Trans. 2014, 43, 
15841–15850. 
[25] S. A. Kularatne, P. S. Low. Methods Mol. Biol. 2010, 624, 249–265. 
[26] H. Tan, Y. Zhang, M. Wang, Z. X. Zhang, X. H. Zhang, A. M. Yong, S. Y. Wong, 
A. Y.-C. Chang, Z.-K. Chen, X. Li, M. Choolani, J. Wang. Biomaterials 2012, 
33, 237–246. 
[27] V. Cauda, A. Schlossbauer, T. Bein. Microporous Mesoporous Mater. 2010, 132, 
60–71. 
[28] T. Kokubo, H. Kushitani, S. Sakka, T. Kitsugi, T. Yamamuro. J. Biomed. Mater. 
Res. 1990, 24, 721–734. 
 
Chapter 8: Conclusions and Recommendations for Future Work  
 153 
Chapter 8  





In order to address the urgent need for better cancer diagnosis, this project reports the 
development of multifunctional PEOSNs, whereby the capabilities of stimuli-
responsiveness, bioimaging (both fluorescent and MRI) and specific targeting are 
effectively combined into a single nanocapsule. In our bottom-up design approach, the 
synthesis parameters required to optimize the size and morphology of PEOSNs and 
MONs were first investigated in a systematic manner. Moreover, the excellent 
biocompatibility and biostability of the nanohybrid shell coating of PEOSNs was 
verified through its in vivo behaviour with transgenic zebrafish line TG(fli1:EGFP) as 
the vertebrate model. 
 
Next, the use of PEOSNs to encapsulate the monodisperse MONs was conducted and 
the resultant PEOMSNs were subsequently characterized for their nanostructure, 
biological behaviour and imaging performance as T1 MRI contrast agents. It was 
demonstrated that the hybrid shell coating of PEOSNs, which consisted of a thin and 
porosified silica shell perforated by the PEO chains of F127 block copolymer, could 
improve the water dispersibility, biocompatibility and r1 relaxivity of the MONs 
significantly due to the rapid penetration of water molecules to the encapsulated 
paramagnetic payload. In addition, several design tenets were also proposed to 
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increase the paramagnetic relaxation enhancement of our nanosystem, namely the 
nanoreactor synthesis of hollow MONs, and the cluster encapsulation of MONs into 
the nanoreactor framework. 
 
Finally, by using the PEOMSNs as a platform, the fluorophore C545T is concurrently 
encapsulated into the nanocapsule core so as to develop an activatable, pH-sensitive 
dual-mode nanoprobe for high performance MRI and fluorescence imaging of cancer 
cells. Our studies have also verified the “ON’-“OFF” characteristics of these dual-
mode cancer nanoprobes as the MON-induced fluorescence quenching is gradually 
recovered when subjected to weakly acidic conditions. This is attributed to the 
increasing solubility of the encapsulated MONs in the acidic environments that can 
occur in the body, such as the endolysosomes or environment of solid tumours. 
Besides, we have successfully conjugated the nanocapsule surface with FA that can be 
recognizable by the specific cells present at the tumour site. Hence, it would ensure 
delivery of the MRI contrast agent and fluorescent imaging agent with great target 
specificity and intensity since the nanocapsules would serve the protect the cargo in 
vivo until they have reached the their destination. 
 
8.2 Recommendations for Future Work 
 
In this study, the biocompatibility of the pH-activatable MnO-based nanoprobe 
(MCNCs) was verified by the in vitro cell viability studies. However, it is conceded 
that these results are insufficient to justify the use of MCNCs in the clinical setting 
and further evaluative tests have to be performed to address the toxicity profile of 
MCNCs thoroughly, for instance haemolysis assay, cell proliferation assay, cell death 
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assay (apoptosis or necrosis) and metabolic assay (protein, DNA, and RNA). In 
addition, it would also be crucial to elucidate the pharmacokinetic properties of 
MCNCs after injection into an animal model so as to ascertain the applicability of 
MCNCs for clinical use. Such determination of the ADME characteristics of MCNCs 
would indicate the potential long-term toxicity arising from the nanoparticles in the 
human body, as well as to quantify for the effectiveness of MCNCs to reach the target 
tissues. 
 
Given that Pluronic® block copolymers are able to sensitize multi-drug resistant cells 
to a few cytotoxic drugs by inhibiting the P-glycoprotein drug efflux system, it would 
also be attractive to tether therapeutic drug into our nanocarrier platform for additional 
drug delivery capability. In this regard, anticancer drugs such as doxorubicin, cisplatin 
or paclitaxel would be particularly suitable for encapsulation due to their hydrophobic 
character, which renders them preferentially sequestered into the hydrophobic core of 
the nanocapsules. It would be desirable to employ the MCNCs as nanoscale vehicles 
to deliver the drugs as it would increase the efficiency of drug delivery into the cancer 
cells, thereby permitting a decrease in the effective dose of the potentially toxic 
chemotherapeutic drugs required for optimal therapeutic benefit. 
 
With regards to materials innovation, the use of organosilanes with organic bridging 
groups, such as methylene (-CH2-) or ethylene (-CH2CH2-), could potentially control 
the permeability of silica shell in our nanosystem. By adding these organosilanes in 
conjunction with TMOS as silica precursors during the interfacial templating scheme, 
it is envisioned that an organosilica shell could be achieved. Herein, the inorganic 
silica framework would yield mechanical strength while the organic component could 
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affect the hydrophobicity of the composite-type silica shell. Consequently, it offers an 
avenue to control the shell permeability and this would have attractive potential for 
controlled release bioapplications. 
